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Executive summary and key research points  
 
Children are entitled to safe, efficacious, and age-appropriate medicines. However, the 
provision of optimal medicines for children is limited by the lack of commercial incentives, a 
dearth of clinical trials on paediatric medicines, delays in licensing medicines for children, 
and the absence of suitable formulations for children. Children are not small adults, but 
rather a vulnerable population with specific needs resulting from their changing physiology, 
who make up a heterogeneous patient group with a scope of diseases different than those of 
adults, and for whom there is a scarcity of data on appropriate medicines delivery and use. 
Therefore, these needs are discussed in detail in this background paper; the challenges and 
opportunities for improvement and further research are also identified. 
 
Demographics and diseases faced by children 
Children in Europe represent 20% of the total population and child mortality rates are low in 
the European Union. Worldwide under-five mortality steadily declined, from 10.4 million in 
2004 to 6.9 million in 2011, but it remains a significant and inequitable problem. Children 
suffer from a different range of diseases than adults, as some diseases only occur in children, 
while others occur in both adults and children, but with different pathophysiology, severity, 
course, and response to treatment across the life span.  
 
Asthma is the most common chronic childhood disease in Europe, affecting 5–20% of school-
aged children in Europe. It is assumed that the recent decrease in the prevalence of asthma 
may correspond with improved environmental control measures. The childhood type 1 
diabetes incidence rate continues to rise across Europe by 3-4% per year, and the risk of type 
2 diabetes in adolescents is increasing due to overweight and obesity. Mental disorders are 
increasingly important causes of ill health and disability in children and adolescents, but the 
recent broadening of age ranges and the scope of diseases has led to debates on the 
medicalisation of certain conditions. Despite the increasing prevalence of chronic diseases, 
infectious diseases remain the most common cause of illness in children in the developing 
world and a predominant cause of childhood mortality in these countries. A study on 
paediatric drug utilisation in Europe (TEDDY) illustrated that anti-infectives, dermatological 
and respiratory drugs were the most frequently used medicines in children.  
 
Product related issues in children 
The 2004 Priority Medicines Report called for public investments to reverse the insufficient 
funding for research on children-specific medicine formulations. An effective paediatric 
therapy requires medicines adjusted to a child’s body development, medicines-related 
toxicity, and the taste preferences of children. To meet these requirements, it may be 
necessary to develop age-appropriate medicines with strengths and dosage forms suitable 
for each paediatric subpopulation using the medicine. 
  
Liquid formulations used to be considered the most suitable form for children under six 
years of age. In 2008, a WHO expert forum proposed a global paradigm shift towards solid 
oral dosage forms for paediatric medicines, and solid, oral, flexible dosage forms 
(orodispersible tablets and tablets for oral liquid preparation) became the recommended 
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paediatric dosage forms. For oral medicines with precise dose measurements, a new flexible 
platform technology was proposed to produce multiparticulate solids (mini-tablets and 
spherical granules - pellets) and dosage forms that are dispersible into liquids or that can be 
mixed with food. The advantages of novel, solid dosage forms are their dose flexibility for 
different patient ages and weights, and their easier administration in younger children. 
Following recent studies on mini-tablets, the age at which young children can safely swallow 
orally administered solid forms is decreasing. With the development of orally disintegrating 
mini-tablets, there are more promising results for infants younger than two years of age.  
 
Recently various innovative, oral, solid dosage forms and drug devices for paediatric use 
have become commercially available or are under development. These developments should 
be accompanied by studies on price implications and access to innovative products, 
children’s preferences and adherence to different dosage forms, safe excipients for children, 
and new routes of administration (mainly for neonates). The industry should implement the 
acquired knowledge about more suitable formulations for paediatric use.  
 
Regulatory aspects related to children 
The European Union adopted the Paediatric Regulation in 2007 to support the development 
and administration of appropriate paediatric medicines and to improve the information 
available on their use. The Regulation combines requirements for paediatric drug 
development (paediatric investigation plans - PIPs) with incentives for the pharmaceutical 
industry to test medicines in children (extension of the supplementary protection certificate - 
SPC and Paediatric Use Marketing Authorisation - PUMA). The long-term aim of the 
Paediatric Regulation is to achieve the goal of an integrated approach to the development of 
paediatric medicines in the overall medicines development area. Nevertheless, paediatric 
therapeutic areas addressed by the industry since 2007 seem more aligned with adult drug 
development than to indicated unmet public health needs of children (paediatric oncology, 
pain, neonatal morbidity). In addition, the awarding of SPC extensions to paediatric 
medicines may increase public expenditures for healthcare and have cost implications for the 
public purse. Such effects have to be identified and negotiated according to the available 
budgets. The fact that only one PUMA has been granted since 2008 indicates that it may not 
be an adequate incentive to the industry for the development of off-patent drugs. As a 
response, a priority list of studies into off-patent paediatric medicines has been produced by 
EMA to serve as a basis for EU public sector research funding. As a complementary measure 
that addresses the lack of paediatric clinical trials for off-patent medicines, existing patient 
records on the use of off-label medicines could be systematically collected and evaluated to 
contribute towards more evidence-based medicines use. Off-label medicines are those 
prescribed outside their authorised indications with respect to age, dosage, indication or 
route. 
 
The paediatric usage environment 
Based on an EMA survey published in 2010, 45-60% of all medicines given to children in the 
EU were used outside their marketing authorisation (off-label), especially in neonates, 
patients with serious conditions and those in intensive care units. The most frequently used 
off-label and unlicensed medicines in children were the anti-arrhythmics, anti-hypertensives, 
proton pump inhibitors, H2-receptor antagonists, anti-asthmatics, and antidepressants. 
Preterm neonates were the most vulnerable patient group, as they were exposed to a high 
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numbers of medicines (mostly unlicensed or off-label), at a higher risk for adverse drug 
reactions, and without information on safety and efficacy in preterms available in the 
Summary of Product Characteristics (SmPC). 
 
Inappropriate antibiotic prescribing for children was common in Europe, with marked 
differences between Northern and Southern Europe as well as difference within countries 
being seen. Of particular concern was the issue of prescribing antibiotics for viral infections 
because of the problem of antibiotic resistance. Antimicrobials were also among the most 
commonly prescribed drugs in hospitals. The European Surveillance of Antimicrobial 
Consumption (ESAC) study in paediatric units in 2008 revealed that a third of paediatric 
patients were on antimicrobials, with a high proportion of them receiving antimicrobial 
combinations. The targets for quality improvement included the excessive use of 
antimicrobial combinations, high proportion of parenteral antimicrobials, and long surgical 
prophylaxis times.  
 
Psychotropic prescribing has risen in European children in the last decade. The most widely 
used drug subclasses have been the selective serotonin reuptake inhibitor antidepressants 
and the atypical antipsychotics. Some of the worrisome aspects of this increased use are the 
lack of well investigated psychotropic medicines, their side-effects (especially long-term 
effects), and the increase in children and adolescents receiving these medications.  
 
Similarly, the irrational use of medications has posed significant challenges for most 
common childhood diseases (pneumonia, diarrhoea, and malaria) in resource poor settings. 
A WHO systematic global review of interventions to improve paediatric treatments 
suggested that the most effective interventions were multifaceted and took place at the 
system level, as opposed to the individual prescriber level.  
 
As definitive data on dosing, efficacy and safety of medicines used in children are seldom 
demonstrated in paediatric trials, concerted efforts are needed to produce universally 
accpeted dosing recommendations in children, derived from an integrated analysis of 
pharmacokinetic and pharmacodynamic data, specific disease factors and developmental 
growth. This is particularly relevant to the frequent off-label use of paediatric medicines, 
which lacks the adequate information about possible indications, dosing regimens, dose 
adjustments, and how they should be administered. Some recent initiatives to improve 
information dissemination on medicines use in children included the new websites 
‘Paediatric Medicines in the Netherlands’, “Medicines for children” in the United Kingdom, 
the British National Formulary for Children and the WHO Model Formulary for Children. 
Nonetheless, it should be explored whether the existing information with precise outcome 
elements within the electronic patient-based system can be utilised to improve the 
prescribing and utilisation of medicines in children in daily clinical practice. 
 
In summary, the following key research priorities for children have been identified: 
 
Collection of data on disease burden and medicines use in children across Europe 
 Use of data on disease burden, prevalence and incidence, as well as medicine use in 
children collected at country level to allow for inter-country comparisons and 
comprehensive EU analysis of trends and variations over time  
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 Improvement of the methodological quality of data collection and provision of EU 
support for more multinational collaborative studies of medicines use in children 
 
Further research into development of age-appropriate medicines 
 Further research on (younger) children's ability to swallow solid oral formulations  
 Study on children’s preferences and adherence to different dosage forms 
 Development of new routes of administration, such as oral-transmusosal (buccal strips), 
intra-nasal and trans-dermal routes (including needs in neonates)  
 More research into safe use of excipients for children, and data sharing within the 
research community 
 Need for additional pharmacological data on optimal dosing, efficacy and safety of 
medicines in children 
 
Study effects of development of age-appropriate medications and paediatric regulations 
 Study the impact of different paediatric formulations on patients’ outcomes 
 Stimulate research on alternative methodological approaches to classical clinical trials to 
facilitate and optimize clinical trials in children   
 Monitor effects of the development of age-appropriate medications and their 
introduction on the national markets (increased public expenditure, poor quality 
products with reference to labelling and packaging) 
 
Increase efficiency of the Paediatric Regulation with a focus on real paediatric needs 
 Indicate clinical trials on certain priority medicines with significant therapeutic benefits 
in children (including neonates) 
 Evaluate new EU Pharmacovigilance Regulation’s potential added value in providing 
safety and efficacy data on off-label-medicines use in children 
 
Improve (information on) rational use of paediatric medicines 
 Collect existing individual (electronic) patient records to produce evidence on safety and 
efficacy of off-label medicines use in children 
 Collect data to measure medicines use in children and assess the effectiveness of 
interventions to improve treatments 
 Evaluate the impact of adherence-promoting interventions in children 
 Evaluate how healthcare professionals obtain information to treat children in daily 
practice  
 Evaluate the impact of new information sources on medicines use in children, on better 
use of medicines and on improved adherence to treatments. 
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1. Introduction 
 
Paediatric patients have specific needs that may not be covered in other parts of the Priority 
Medicines for Europe and the World 2013 report, since children suffer from a different range 
of diseases than adults. They are a heterogeneous patient group with developmental, 
physiological, and psychological differences between age groups and from adults. The 
provision of optimal medicines for children is limited by various barriers that include 
insufficient research in children, delays in licensing medicines for children, inadequate 
development of appropriate formulations for children, and knowledge deficiencies that 
would enable optimal prescribing. 
 
This background paper provides an update on the activities undertaken to provide optimal 
medicines for children since the previous version of the report published in 2004. It identifies 
knowledge gaps related to children and discusses potential areas for further research, 
identifying issues that need more attention and analysis in the future.  
 
 
2. Demographics and diseases faced by children 
In this section, we will concentrate on childhood mortality, as well as the diseases that are 
most prevalent in children. We will provide an overview of their trends over time, identify 
novel insights that have been gained since 2004, and discuss the strategies needed to 
decrease disease burden in childhood. This section complements Background Paper 5 of the 
report on general demography, and various parts of Chapter 6 that cover additional 
childhood conditions (neonatal morbidity, infectious diseases and pneumonia, childhood 
cancers, orphan diseases, etc.). Nevertheless, we do not intend to provide a full overview of 
research gaps in the management of specific childhood diseases. 
 
Additionally, patterns of general medicines use are studied to provide data about the 
suboptimal use of medicines, uncover undesirable prescribing practices in childhood 
diseases, and inform decisions on the prioritisation of research.  
 
2.1 Childhood mortality 
Most children and adolescents in the European Union enjoy a high standard of health and 
well-being. The paediatric population (0-18 years) represents about 100 million people or 
20% of the total population. The crude birth rates have increased modestly from 10.4 in 2004 
to 10.7 births per 1 000 inhabitants in 2010, with 5.4 million children having been born in 
2010.1, 2  
 
The child mortality rates are low in the European Union. The average EU mortality rates in 
the first year of life declined from 5.1 deaths in 2004 to 4.2 deaths in 2010. Annex 7.1.1 shows 
that the rates ranged from three deaths per 1 000 live births in most Nordic countries, 
Portugal, Slovenia, and the Czech Republic, up to 9.4 and 9.8 deaths per 1 000 live births in 
Bulgaria and Romania respectively, and 13.6 deaths in Turkey.3 An infant`s risk of dying in 
Europe is greatest during the first four weeks of life. According to the statistics, two-thirds of 
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neonatal deaths in the first year of life occurred due to prematurity, congenital abnormalities 
and birth asphyxia.3 
In the WHO European region, 160 000 children died before the age of five in 2010. As shown 
in Annex 7.1.2, half of them were neonatal deaths (49%), related to preterm birth or intra-
partum complications, congenital anomalies, neonatal disorders, sepsis, or meningitis.4 
Other common causes for death in children under age five were pneumonia, injuries, 
diarrhoea, and undefined disorders.4 
 
Worldwide, under-five mortality has steadily declined from 10.4 million in 2004 to 6.9 
million in 2011.5 The most significant causes of death in children under the age of five 
worldwide were pneumonia, preterm birth complications, diarrhoeal diseases, child birth 
complications, and, malaria. About 40% of children younger than five years of age died 
during the neonatal period due to preterm birth complications, birth sepsis, and asphyxia.4 
(Figure 7.1.1)   
 
In older age groups, infectious diseases, HIV and tuberculosis, injuries, and some cancers 
predominated, although overall mortality was lower.5,6 During adolescence, the leading 
causes of death were accidents, suicide, violence, pregnancy related complications, 
communicable diseases (tuberculosis, meningitis, and HIV/AIDS), and non-communicable 
diseases (diabetes and cancer).7 
 
 
Figure 7.1.1: Global causes of childhood deaths in 2010 
 
Source: Liu L, Johnson HL, Cousens S, et al, for the Child Health Epidemiology Reference Group of 
WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic 
analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151–614 
 
2.2 Childhood morbidity 
Children suffer from a different range of diseases than adults. Firstly, some diseases such as 
prematurity, congenital abnormalities, respiratory distress, certain leukaemias, or genetic 
conditions like phenylketonuria only occur in children. The diagnosis, prevention and 
treatment of these conditions cannot be adequately investigated without studying children. 
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Secondly, other conditions, such as influenza, asthma, mental health problems, certain 
cancers, and forms of arthritis, occur in both adults and children, but their pathophysiology, 
severity, course, and response to treatment may differ across the life span. Thus, treatments 
that are safe and effective for adults may be dangerous or ineffective for children. 
Furthermore, certain diseases like asthma and psychiatric disorders may start in childhood 
and continue into adult life, so effective treatment at an early stage of the disease may be 
beneficial. Also, lifestyles started in childhood may lead to chronic diseases later (e.g. 
hypertension, obesity, diabetes mellitus, asthma, and mental diseases). Therefore, research in 
children is necessary to establish the causes and natural history of diseases and to enable the 
employment of primary prevention strategies to counter risk factors and behaviours in 
childhood and adolescence.8 
 
2.2.1 Asthma in children 
Asthma is the most common chronic childhood disease in Europe, affecting 5–20% of school-
aged children in Europe.9 Its prevalence varies widely across Europe, with a rate up to ten 
times higher being reported in Western Europe than in Eastern Europe, possibly due to 
different exposure to respiratory infections, pollution and diet.10 On the other hand, under-
five morbidity rates are not known because most surveys, including the International Study 
of Asthma and Allergies in Childhood (ISAAC; 1993-2003), have not studied this age group.11 
The underlying reasons are the difficulties in making a confident diagnosis of asthma and 
the variability of wheezy phenotypes in very young children.12 The global ISAAC research 
has been discontinued, but new evidence coming from high-prevalence European countries 
showed that childhood asthma rates increased steadily for several decades and then levelled 
off, or even declined. In a study of six to nine year-old Irish children, the asthma prevalence 
remained stable at 21.7% in 2002 and 23.5% in 2007.13 Moreover, a respiratory health survey 
of primary school children in England showed a significant decrease in the prevalence of 
asthma, wheezing, and allergies between 1998 (29.8%) and 2006 (19.4%), coinciding with 
improved environmental control measures in the area.14 
 
Asthma affects lung growth in children, which is a determinant of lung function in adult life, 
so optimal treatment is of major concern for long-term prognosis.15, 16 In recent years, several 
efforts have been made to provide a uniform definition of asthma severity, and to improve 
knowledge about its pathophysiology, prevention, diagnosis, treatment, and monitoring.12,17 
In 2007, a project funded by the EU's Sixth Framework Programme (GABRIEL) succeeded in 
identifying new genetic markers that raise the risk of asthma in infancy.18 However, given 
the heterogeneity of asthma, the identification of its diverse childhood phenotypes, including 
those that develop into adult asthma, still remains. The identification of these diverse 
phenotypes will further contribute to a more personalised patient approach.19  
  
2.2.2 Diabetes in children 
According to the European diabetes registry, EURODIAB, the type 1 childhood diabetes 
incidence rate continues to rise across Europe by 3-4% per year. During the period of 2004-
2008 incidence rates varied from 5.8 per 100 000 in the Republic of Macedonia to 36.6 per 100 
000 in the Stockholm area of Sweden. The evidence pointed to an interplay between genes 
and environmental factors (e.g. lifestyle, diet, virus infections), which may differ between 
populations.20 Between 2005 and 2020, EURODIAB research has estimated a doubling of new 
cases of diabetes in children under five years of age and an increase of the prevalence in the 
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under 15-year-olds by 70%. The most striking changes over time are expected in central and 
eastern European countries with currently lower incidence rates,21 presumably due to 
improvements in their case detection and detrimental changes in their lifestyle habits. Type 1 
diabetes is the most prominent form of diabetes seen in childhood, especially in children 
under 10-years-old. However the trend towards overweight and obesity is driving the 
development of type 2 diabetes in youths, particularly after the onset of adolescence.22 
 
2.2.3 Mental diseases in children 
Mental disorders are increasingly recognised as a significant causes of ill health and 
disability in children and adolescents globally, including Europe.23 Research has shown that 
mental health is the largest contributor to the burden of disease in young people aged 10–24 
years (45%), clearly ahead of unintentional injuries (12%) and infectious and parasitic 
diseases (10%).7 In Europe, the prevalence of mental illness prior to 2004 was 8-23% in the 
child and adolescent population.24 For the 2010 study on mental and neurological disorders 
in the EU, the European Brain Council broadened the age range and scope of diseases 
studied, including childhood and adolescence brain disorders. According to the age-specific 
data, an estimated 3 million children suffered from attention-deficit hyperactivity disorders 
and hyperkinetic disorders, 0.6 million from pervasive developmental disorders (e.g. autism, 
Asperger's syndrome), and 2.1 million from conduct disorders.25 Similarly, bipolar disorder 
has been progressively more often diagnosed in children, despite the previous psychiatric 
consensus that manic-depressive illness rarely has its onset before adolescence.26 The total 
disease burden of paediatric mental health diseases has not yet been fully elucidated because 
of the many complexities involved, in terms of defining diagnostic categories and health 
measurements in children. It is a well-established fact that many of the mental disorders seen 
in children can be precursors of much more disabling disorders in later life.27 On the other 
hand, the increased prevalence rates led to debates on the medicalization of certain 
conditions, the diagnostic validity and the true size of mental disorders.28, 29  
  
2.2.4 Infectious diseases in children 
Despite improved living conditions and health care (e.g. use of antibiotics and vaccines), 
infectious diseases remain the most common cause of illness in children in the developing 
world and are a predominant cause of childhood mortality in these countries.4 In the 
category of infectious diseases, the most serious are acute respiratory diseases (including 
pneumonia and influenza), HIV/AIDS, diarrhoea, tuberculosis, malaria, and measles.4 Even 
though the prevalence and burden of infectious diseases is much lower in Europe4, their 
public health effects extend beyond direct disability and death. Increased global mobility can 
lead to an increased risk of epidemics, while the irrational use of medicines can contribute to 
the emergence of antimicrobial and multidrug resistance, further complicating the 
management of subsequent infections. Thus, new and re-emerging infectious diseases 
present a global health concern, which necessitates investments in effective surveillance 
networks and targeted prevention and intervention strategies. For more information on 
infectious diseases and resistance, see the background paper on antimicrobial resistance 
(6.1).  
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2.3 General use of medicines in children  
A literature review (1994-2008) on drug utilisation in paediatric outpatients found only a few 
countries involved in research (mostly from Europe and North America) and large 
differences between studies with regards to data source, sample size, and age range. The 
drug utilisation prevalence rate was higher in preschool children and lower in older 
children.30 More than half of the children (51-70%) in outpatient care received at least one 
medication. Each child treated received, on average, between 1.3 and 5.3 prescriptions, and 
60% of children received an average of three drug prescriptions in a one-year period. 
Antibiotics were the most frequently prescribed drugs (20–33% of all prescriptions), followed 
by anti-asthmatics (10–25%).30 
 
Patterns of paediatric drug utilisation in Europe were specifically studied using three 
population based databases from Italy, the United Kingdom and the Netherlands for the 
period 2000-2005. The analysis revealed that prescription rates were highest for children less 
than two years of age, and they were higher in the United Kingdom and Italy when 
compared to the Netherlands in each of the age groups. Furthermore, certain gender patterns 
were observed with more prescriptions being written for girls than for boys after the age of 
ten, as opposed to the pattern seen in the younger age groups. The user prevalence rates for 
the year 2005 showed that anti-infective, dermatological, and respiratory drugs were in the 
high-use group for all age categories, whereas cardiovascular and anti-neoplastic drugs were 
in the low-use group, corresponding to the childhood morbidity rates.31 (Figure 7.1.2)  
 
 
Figure 7.1.2: Year prevalence of drug use (per 1000 person years) by age (<2, 2-11, 12-18), 
country, and anatomical class for most prevalently used drug classes (data for Italy 
excluded age category 12-18) 
he  
Source: Sturkenboom MC, Verhamme KM, Nicolosi A, et al; TEDDY European Network of Excellence. 
Drug use in children: cohort study in three European countries. BMJ 2008;337:a2245.31 
 
 
 
This general drug use overview, based on multiple European paediatric populations, was 
conducted for the TEDDY (Task Force in Europe for Drug Development for the Young) 
project, co-funded by the European Commission within the Sixth Framework Programme 
(2005-2010).32 Lamentably, no similar initiative in the paediatric field, including a wider 
range of countries and more recent data, has been supported with EU funding. 
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2.4 Conclusions  
Addressing the gaps and identifying future priorities for paediatric medicines requires 
information on burden of diseases and use of medicines in children. Data routinely collected 
at national or local levels can prove to be a valuable source for inter-country comparisons 
and comprehensive EU analysis of trends and variations over time. Although individual 
countries and research communities may study particular aspects of childhood diseases and 
maintain prescription databases, the process of data gathering and analysis at the EU level is 
not very common. The lack of systematic and continuous monitoring in all EU countries and 
the heterogeneity between studies make comparative evaluations difficult or incomplete. 
Therefore, the methodological quality of data collection should be improved, and more 
multinational collaborative studies should be performed with EU support.  
 
 
3. Product related issues in children 
 
It is well established that children are not small adults, but rather distinct entities with 
regards to pharmacotherapy. First, they differ from adults with regards to their body 
development, their medicines related toxicity and their taste preferences.33 As a result, an 
effective paediatric therapy requires medicines adjusted to the needs of children. Second, 
children are a heterogeneous patient group that may need age-appropriate medicines 
suitable for each paediatric subpopulation. These two important factors affecting drug 
delivery in children require novel formulations with dose flexibility and also medical devices 
for easier administration of paediatric medicines, as discussed in this section. 
 
3.1 Paediatric age-appropriate dosing and formulations 
Children are different from adults in many respects, including their body development, 
pharmacokinetics and pharmacodynamics. Infants have slower gastrointestinal, but faster 
intramuscular (IM) absorption, limited protein binding and immature enzymes.34 Their livers 
are immature and may not metabolise drugs as rapidly as expected; their kidneys are also 
small and immature. Drug distribution is also different because a neonate´s body contains 
80% water (adult proportion is 55–60%), and the water is distributed more into the 
extracellular than into the intracellular space when compared to adults. Furthermore, 
children have larger liver/body and brain/body weight ratios and higher blood–brain barrier 
permeability, and small infants often have a two to three times longer half-life for 
elimination of medicines than adults, requiring lower doses of medicines. Consequently, 
even when a medicine has a known effect in adults, a linear dose-per-kg correlation often 
does not hold true with regards to small children, as shown in Annex 7.1.3.33,35   
 
Given the information above, it is clear that paediatric dosage regimens cannot simply be 
extrapolated from adult data, as an effective therapy requires medicines adapted to the 
needs of children. In addition, the knowledge on optimal dosing for efficacy and safety is 
very important for deciding on the appropriateness of a formulation. It is vital to consider 
the ‘criticality’ of the dose (i.e. steep dose/pharmacodynamics response curve, narrow 
therapeutic window) and the dosing regimen (i.e. dose calculation, dose titration, flexibility 
of dosing).36  
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The purpose of good paediatric formulations is to achieve safe and accurate dose 
administration, reduce the risks of medication errors and enhance medication compliance.37 
Selection of appropriate formulations should be based on a case-by-case basis, including the 
age, size, condition of the child (e.g. critical illness, concomitant medication, ability to 
swallow dose), usage environment, and the expected duration of the therapy.38 
Further basic criteria for paediatric medicines include:  
 sufficient bioavailability  
 minimal dosage frequency  
 safe excipients  
 minimum impact on lifestyle  
 good taste acceptance  
 socio-cultural acceptability  
 clear product information39 
 
The development of suitable paediatric medicines is a complex task with a range of technical 
challenges, such as:  
 diversity of children  
 accuracy of dosing with lower paediatric doses and volumes  
 inability to swallow solid dosage forms  
 taste masking in oral forms  
 stability and unsafe excipients  
 needle phobia and small veins for parenteral forms, etc.39 
 
Body size and weight increase up to twentyfold from birth to adulthood, and the magnitude 
of doses administered throughout childhood can vary a hundredfold. Plus, the ability to take 
medicines (i.e. cognitive and motor skills, dependence on caregivers) and dosage form 
preferences differ greatly across the age spectrum.38 Accordingly, it may be necessary to 
develop age-appropriate medicines with strengths and dosage forms suitable for each 
paediatric subpopulation using the medicine.38 Table 7.1.1 and the EMA Matrix (Annex 7.1.4) 
illustrate suitable dosing and dosage forms as a function of the child’s age. 
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Table 7.1.1 Change in magnitude of dose and the ability to cope with dosage forms 
BNFC1 age-based dosing guidelines for Paracetamol 
Age Dose 
Baby 30 - 60 mg 
1 year  60 - 120 mg 
6 years 120 - 250 mg 
12 years 250-500 mg 
Adolescent 0.5-1 g 
  
Change in ability to cope with dosage forms 
Age Dosage forms 
Baby drops 
1 year liquid, ‘melts’ 
6 years liquid, tablets, ‘melts’ 
12 years tablets 
Adolescent tablets/capsules 
  
1 British National Formulary for Children 2006 
 
Source: Nunn T. Presentation: Age-appropriate formulations – paediatric needs. EMA Workshop on 
Paediatric Formulations II 8 November 2011 
http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/01/WC500121603.pdf. 
Accessed April 29, 2013.40 
 
 
 
3.2 New oral paediatric formulations 
In general, oral formulations are preferred for long-term use in children, whereas parenteral 
administration is likely to remain the first choice during the neonatal period and for 
emergency cases. Alternative routes of administration under investigation include 
transdermal (for constant blood levels), or the less invasive buccal, nasal and pulmonary 
drug delivery systems.38  
 
Tablets have not been ideal dosage forms for all paediatric patients due to difficulties in 
swallowing and in the division of the tablet dose based on weight. Thus, liquid formulations 
used to be considered the most suitable for children less than six years of age3838, despite their 
major disadvantages such as chemical, physical or microbial instability, taste issues, and lack 
of controlled release properties.41 In 2008, a WHO expert forum proposed a paradigm shift 
towards solid, oral dosage forms for paediatric medicines, in view of stability problems with 
liquid formulations in different climate zones and the high costs of their transportation and 
storage.42 Oral, solid flexible dosage forms, such as orodispersible tablets, and/or tablets used 
to prepare oral liquid preparation suitable for younger age groups became the recommended 
paediatric dosage forms for global use.42 The following year, Coartem® Dispersible was the 
first dispersible artemisinin-combination therapy for children (5-35 kg) launched in Africa by 
Novartis and the Medicines for Malaria Venture.43 A clinical study in Tanzania confirmed a 
high cure rate of 97.8% with the pleasant tasting suspension, comparable to that of the bitter 
Coartem® tablet (98.5%).44 
 
For oral medicines requiring precise dose measurement, a new flexible platform technology 
was proposed to produce multiparticulate solids (mini-tablets and spherical granules – 
Update on 2004 Background Paper, BP 7.1 Priority Medicines for Children 
 7.1-16 
pellets) and dosage forms dispersible into liquids or to be mixed with food.42 Since then, 
various innovative oral, solid dosage forms for paediatric use, such as multiparticulate and 
flexible dispersible solids, have been commercially available or are under development. 
(Table 7.1.2 and Annex 7.1.5 for branded products).43,45  
 
 
Table 7.1.2:Novel oral drug formulations for children 
Multiparticulates  Flexible dispersible formulations Other oral preparations 
Granules Dispersible tablets Chewable tablets 
Sprinkles Oral lyophilistaes  Gummy bears 
Pellets Orally disintegrating tablets – lozenges  Chewing gum 
Mini-tablets Oral strips / Buccal wafers  
 Medicated lollipop (melt-away lozenge with applicator)   
 Orally disintegrating mini-tablets (experimental)  
Sources: Stoltenberg I, Winzerburg G, Breitkreutz J. Solid oral forms for children – formulations, 
excipients and acceptance issues. Journal of Applied Therapeutic Research, 2010; 7(4): 141-146.43  
Breitkreutz J. Nach der EU-Reform. Arzneiformen für Kinder. Pharm. Unserer Zeit 2009;38: 30-374545 
 
 
 
The advantages of these novel, solid dosage forms over the conventional ones are not only in 
their dose flexibility for different patient ages and weights, but also in their ease of 
administration in younger children.46 For a while, there have been concerns and uncertainties 
about the age at which young children can safely swallow orally administered tablets and 
capsules. It is generally accepted that the age at which children can swallow intact tablets or 
capsules is highly dependent on the individuals and the training and the support they 
receive from healthcare professionals and caregivers.36 The matrix combining different age 
groups, routes of administration and dosage forms, developed by EMA (Annex 7.1.4), 
reflects on the variability in children’s ability to swallow solid dosage forms. EMA considers 
tablets as potentially acceptable from the age of three.36 Studies have reported tablet use in 
three year-old children for the treatment of long-term illnesses.47  
 
However, in 2009 the acceptability of and the ability to swallow these innovative mini-tablets 
(3 mm in diameter) was explored in children aged two to five years. Forty-six per cent of the 
children aged two years, and up to 86% of the five-year-old children swallowed the mini-
tablets; no children choked or aspirated the mini-tablets. To improve the acceptability of 
mini-tablets by parents, suitable dosing devices that automatically count a variable number 
of mini-tablets or electronic dispensers were suggested.48 
 
A recent exploratory study illustrated a high acceptance and ability of children aged 0.5–6 
years to swallow uncoated drug-free mini-tablets (2 mm in diameter) compared with a sweet 
testing syrup.49 (Figure 7.1.3) The study is currently being repeated with a larger cohort to 
confirm safety and to explore whether the observed chewing before swallowing has an 
impact on the usability of uncoated mini-tablets. Its results may convince the EMA to 
consider uncoated 2 mm mini-tablets for children aged six months in its new guidelines.49 
 
  
Update on 2004 Background Paper, BP 7.1 Priority Medicines for Children 
 7.1-17 
Figure 7.1.3: Children’s ability to completely swallow mini-tablets and glucose syrup 
(n=10 children per age group; mean ± 95% CI). 
 
Source: Spomer N, Klingmann , Stoltenberg I, et al. Acceptance of uncoated mini-tablets in young 
children: results from a prospective exploratory cross-over study. Arch Dis Child 2012;97:283–286.49  
 
 
 
There are more promising results coming for infants younger than two years with the 
development of orally disintegrating mini-tablets (ODMTs) — a novel, solid oral dosage 
form that combines mini-tablets and fast-dissolving dosage forms. A 1 mg ODMT was 
produced as a novel paediatric medicine using the diuretic hydrochlorothiazide. The aim 
was to offer a suitable therapeutic option for very young children, as only tablets and 
capsules of 12.5 mg are available on the market. The ODMT was manufactured with safe 
excipients and it has passed all required laboratory tests. Further investigations, with regard 
to taste masking, dissolution, advanced suitable dosing systems, and acceptability still have 
to be performed.50 
 
The innovations regarding paediatric formulations remain to be implemented by the 
industry during the process of the development of medicines for paediatric use. The new 
technologies must be applied outside the academic setting, in particular where dosing 
flexibility, taste masking and administration flexibility is needed. 
 
3.3 Novel paediatric drug devices  
Some of the obstacles and limitations in ensuring the delivery of a correct dose born by 
currently available paediatric formulations can be overcome by new technologies. Over 100 
patents have been filed for novel paediatric dosing devices in order to ensure the accurate 
and consistent administration of paediatric formulations.39 The majority of these patents 
relate to the delivery of liquids to very small children orally, such as modified feeding 
bottles, modified pacifiers and teats with the required dose of medicine placed in a 
reservoir.39 Also, the dose sipping technology, consisting of a straw with film-coated micro-
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pellets ingested in a liquid of choice, has been developed to improve the problem related to 
the palatability of oral solution. The manufacturer’s internal studies showed an improved 
adherence in children, but compatibility studies with the drink are still required.3939 
 
 
Table 7.1.3:Novel drug devices for children 
Novel dosing instruments for oral liquids 
Teat/Pacifier with reservoir  
Single-use spoon filled with medicine 
Dropper tube 
Dose sipping technology - straw with taste 
Solid dosage pen 
 
Coated particles for oral administration 
Coated particles on dosage spoon 
Coated particles in suspension 
Coated particles in tablets for preparing a suspension 
Coated particles on dosage spoon  
 
Needle-free injection devices 
Jet injectors (drive small droplets through the skin by high pressure) 
Microstructured transdermal systems for intradermal vaccines 
 
Novel devices for inhalation therapy 
Nebuliser with spacer/valved holding chamber and face mask 
Nebulisers with a vibrating mesh technology for aerosol generation 
Nebuliser with an electronic unit 
Dry powder inhalers 
Sources: Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Exp Opin Drug Deliv 2007; 4:37–
4539 
Walsh J,Bickmann D, Breitkreutz J, Chariot-Goulet M, on behalf of the European Paediatric 
Formulation Initiative (EuPFI). Delivery devices for the administration of paediatric formulations: 
Overview of current practice, challenges and recent developments. International Journal of 
Pharmaceutics 2011;415:221– 23151 
 
 
 
Table 7.1.3 and Annex 7.1.6— listing branded products, provide an overview of currently 
available paediatric administration devices for the parenteral, oral, and inhaled 
administration of paediatric formulations. However, although many paediatric drug 
delivery devices have been developed, some of which may offer tangible patient benefits, 
there appears to be very few available on the current market. This is likely due to their high 
costs, as many novel technologies are protected by patents, and to the (un)willingness of 
health insurance bodies to reimburse for the use of these devices.51 
 
3.4 Taste and palatability of paediatric dosage forms 
Paediatric dosage forms must also be designed to ensure patient compliance, either by 
having a minimal impact on lifestyle or by having an appropriate appearance (colour and 
palatability) especially for oral liquids and powders.52 It is often difficult to assess the taste 
attributes of the drug formulation, particularly in younger children who are not capable of 
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expressing their taste sensations and mouth feelings adequately. In addition, taste masking 
of certain solid paediatric dosage forms, such as chewable tablets or fast dissolving 
preparations (e.g. orodispersible tablets and films), can be particularly challenging, 
especially for high solubility drugs that dissolve rapidly in the mouth.52  
 
Some paediatric formulations take into account the individual taste preferences of the child. 
Examples include Children’s Tylenol® with ‘Flavor Creator’, where sachets of different 
flavouring agents can be added to the liquid prior to administration. A similar concept is that 
of the FLAVORx™ system, which consists of various flavours that can be added to oral 
medications to improve palatability, and that has been used in Thai AIDS patients to increase 
adherence with antiretroviral medicines.53 The limitation of this approach is that the 
compatibility of the flavours with the medication is often unknown, potentially impacting 
formulation stability.53 Another example is the previously mentioned dose sipping 
technology using a drinking straw with taste-masked granules.52 
 
Alternative approaches to facilitating taste masking of paediatric solid preparations include 
the coating of a drug substance prior to incorporation into formulations or the film-coating 
of small dosage forms such as pellets or mini-tablets. It is essential that all taste masking 
approaches are guided by the specific safety considerations of paediatric drug 
development.52 
 
3.5 Use of excipients in paediatric dosage forms  
One critical element in the development of paediatric formulations is the selection and use of 
excipients, as their safety in paediatric subpopulations is often unknown. As a result of age 
differences, there are elevated toxicological risks in young children for some excipients, such 
as ethanol, propylene glycol, benzyl alcohol, polysorbate, parabens, etc. (Table 7.1.4) in their 
metabolism and elimination as compared to adults.39 In 2011, the FDA issued a drug safety 
communication and changed the drug label of Kaletra® (lopinavir/ritonavir) because of some 
serious health problems that arose in premature newborns related to the propylene glycol 
contained in the oral solution.54 In 2012, the EMA issued a concept paper to get input from 
the public on revisions to its excipient guidelines on labelling and packaging in order to 
include safety concerns for paediatric populations and pregnant women, since the current 
2003 guidelines do not address these safety issues.55  
 
 
Table 7.1.4: Excipients with elevated toxicological risks for the paediatric population 
(preterm and term neonates, infants less than 6 months of age 
Excipient Administration Adverse reaction 
Benzyl alcohol Oral, parenteral Neurotoxicity, metabolic acidosis 
Ethanol Oral, parenteral Neurotoxicity 
Polyethylene glycol Parenteral Metabolic acidosis 
Polysorbate 20 and 80 Parenteral Lives and kidney failure 
Propylene glycol Oral, parenteral Seizures, neurotoxicity, hyperosmolarity 
Source: Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Exp Opin Drug Deliv 2007; 4:37–
4539 
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Even though the demand for paediatric data on the safety of excipients has grown 
considerably, there is very limited paediatric excipient safety data, and it is distributed 
throughout many sources.56 As a result, the EU and the United States Paediatric Formulation 
Initiatives are creating a Database of Safety and Toxicity of Excipients for Paediatrics (STEP) 
to incorporate this safety data into a single comprehensive and readily accessible database. 
This repository of excipient information (e.g. dose information, pharmacokinetics (PK)) is 
expected to provide a basis for screening and selecting excipients for use in paediatric 
product development and further accelerate product-specific safety and toxicity studies. The 
first prototype version database was launched in 2012.56 
 
To support the task of safe use of medicines in children, there is an urgent need for concerted 
action toward obtaining the missing data on safety of excipients for paediatric use. While the 
companies are responsible for providing data on safety of excipients in paediatric medicines, 
EU programmes are also needed to fund related research activities and fill this information 
gap. 
 
3.6 Clinical evidence on impact of paediatric pharmaceutical 
development 
Despite all the research on novel paediatric products, the literature suggests limited clinical 
evidence to support pharmaceutical development programmes in children. A recent 
systematic review identified 94 articles on oral medicines for use in children and adolescents 
that reported the effects of three pharmaceutical technologic aspects (formulation and 
dosage form; route and frequency of administration; and packaging, administration device, 
and user instruction) on six patient-related outcomes (clinical efficacy, side effects and 
tolerability, patient preference, patient acceptance, administration errors, and adherence). 
The majority of the studies (90%) were conducted on children aged 2 to 12 years, which can 
be explained by a lack of clinical trials in neonates and infants, as a result of the limited 
market potential of products for this population. Only two publications were of good 
methodologic quality, suggesting that paediatric pharmaceutical development studies may 
need more suitable instruments to measure their methodological quality, as randomized 
controlled and double blind trials might not be always appropriate. Table 7.1.5 demonstrates 
that side effects, tolerability and administration errors received limited attention, resulting in 
no evidence being available to substantiate that improved formulations lead to fewer side 
effects.57   
 
Based on the study findings, the authors encouraged an agreement on taxonomy of 
pharmaceutical technological aspects and patient-related outcomes, and the creation of a 
global database with literature on the development of paediatric pharmaceuticals to promote 
research in these neglected areas.57  
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Table 7.1.5: Impact of pharmaceutical technologic aspects on patient-related outcomes 
parameters.  
 Pharmaceutical Technologic aspect  
Patient-Related Outcomes 
Parameter 
Formulation and 
Dosage Form 
(n=85) 
Route and 
Frequency of 
Administration 
(n=77) 
Packaging, 
Adminstration 
Device, and User 
Instruction (n=14) 
All Assessments 
(n=176) * 
Patient acceptance  38 (45) ** 5 (6) 1 (7) 44 (25) 
Patient preference 19 (22) 4 (5) 0 23 (13) 
Adherence 11 (13) 15 (19) 6 (43) 32 (18) 
Clinical efficacy 8 (9) 31 (40) 2 (14) 41 (23) 
Side effects and tolerability 8 (9) 22 (29) 0 30 (17) 
Administration errors 1 (1) 0 5 (36) 6 (3) 
* Two investigations assessed >1 pharmaceutical technologic aspect.  
** Data are number (%) of assessments 
 
Source: van Riet-Nales DA, Schobben AF, Egberts TC, Rademaker CM. Effects of the pharmaceutical 
technologic aspects of oral pediatric drugs on patient-related outcomes. Clin Ther 2010;32(5):924-3857 
 
 
 
3.7 WHO activities towards better medicines for children  
To address the lack of child-specific medicines, the Member States of the World Health 
Organization (WHO) passed a resolution on ‘Better Medicines for Children’ WHA 60.20 
during the 2007 World Health Assembly. The resolution mandates the WHO to explore ways 
to promote more research and development into paediatric medicines and to improve 
knowledge on the quality, effectiveness and safety of these medicines. 
 
Following this breakthrough event, the WHO commenced work on a number of activities to 
improve the availability of better medicines for children. In December 2007 the WHO 
launched its initiative ‘Make medicines child size’58 in order to raise awareness and to 
accelerate action in order to meet the need for improved availability and access to child-
specific medicines. The same year, the WHO Subcommittee on Selection and Use of Essential 
Medicines developed the first Model List of Essential Medicines for Children,59 and has been 
revising and updating it every two years to include missing essential medicines for children, 
using evidence-based clinical guidelines. The list was developed to serve as a reference for 
countries in developing national lists according to their specific public health priorities and 
to ensure that child-specific medicines are developed and delivered to the intended patient 
groups. As a follow up, the WHO Model Formulary for Children was created in 2010 to 
provide independent prescriber information on dosage and treatment guidance for 
medicines based on the WHO Model List of Essential Medicines for Children. The 
publication ‘Sources and Prices of Selected Medicines for Children’60, produced annually by 
UNICEF and the WHO, identifies the sources and prices for selected products used in the 
treatment of childhood diseases and contributes to the effort to increase access to appropriate 
medicines. 
 
As part of the ‘Better Medicines for Children Project’, funded by the Bill and Melinda Gates 
Foundation, the WHO has also helped in the foundation of an international regulatory 
working group (Paediatric Medicines Regulatory Network)61, responsible for reviewing 
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existing regulatory standards and enhancing the availability of quality medicines for 
children by facilitating communication, collaboration, and regulatory coordination across the 
areas of manufacturing, licensing, and research. The Paediatric Medicines Regulators 
Network recently contributed to the development of the Guidance on Assessing Clinical 
Trials in Children, as well as the important documents ‘Development of paediatric 
medicines: points to consider in formulation’46 and a review on extemporaneous or 
compounded formulations.  
 
Simultaneously, the WHO International Clinical Trials Registry Platform (ICTRP) launched 
the Clinical Trials in Children website,62 with the aim of improving research transparency 
and making it easier to access accurate, up-to-date and understandable information relevant 
to the conducting of clinical trials in children.  
 
In 2012, the list of ‘Priority life-saving medicines for mothers and children’ was updated,63 
highlighting the most important medicines for mothers and children that should be readily 
available throughout health systems. The list was compiled according to the global burden of 
disease and is based on evidence of efficacy and safety. Medicines were selected from the 
Model List of Essential Medicines and are included in current WHO treatment guidelines. 
Medicines for pneumonia, diarrhoea, malaria, neonatal sepsis, HIV/AIDS, and vitamin A 
deficiency are included on the priority list for children under five. Treatments for palliative 
care and pain for all children are included as well.  
 
Additionally, the WHO Prequalification of Medicines Programme has been prequalifying 
new products specially designed to treat HIV/AIDS in children,64 which is considered to be 
one of the priority paediatric treatment areas (Annex 7.1.7). The product prequalification 
represents a considerable advance in making user-friendly formulations that improve 
efficacy of treatment available. 
 
Overall, the WHO has made progress on several fronts: essential tools, such as treatment 
guidelines and information on the use of essential medicines have been developed and 
published; relevant professional groups have been engaged; and key studies have been 
initiated. Further research and development for appropriate formulations, such as fixed-dose 
combination products, is expected to be directed towards paediatric tuberculosis treatment 
and treatment of HIV in young infants.  
 
3.8 Conclusions 
Much progress has been made in the development of age-appropriate paediatric 
formulations, especially those for oral administration. The current formulation research has 
been directed towards mini-tablets, chewable and dispersible tablets for younger children. 
Nevertheless, the ongoing research into the ability of children to swallow medication needs 
to be accompanied by studies on children’s preferences and adherence to different dosage 
forms. In addition, new routes of administration such as oral-transmusosal (buccal strips), 
intra-nasal, and trans-dermal routes (for neonates mainly) are ripe for future developments 
and research. In neonates, particular caution is needed for these forms in terms of optimal 
use and dosing. 
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More research into alternative safe excipients for children is also expected, given the safety 
and toxicity concerns of some excipients in paediatric formulations. Yet, it is also essential to 
incorporate the available knowledge on excipients, generated through individual research, 
into a single and public repository. It would be helpful in avoiding a duplication of efforts, 
and encourage further discovery and innovation.  
  
Despite all the technologic progress, the published clinical evidence on the impact of 
different paediatric formulations on patients’ outcomes is still limited. This research should 
be central in order to support pharmaceutical development of paediatric medicines.  
 
 
4. Regulatory aspects related to children 
 
For years, the lack of information about the safety, efficacy and dosing data of paediatric 
medicines, as well as the lack of child-appropriate formulations resulted in the unsatisfactory 
treatment of paediatric patients. Healthcare professionals were left with no alternative but to 
use off-label and unauthorised products with their associated risks of inefficacy or adverse 
reactions (see Section 5 of this background paper). The lack of suitable, authorised medicinal 
products to treat conditions in children can be best explained by the fact that frequently 
pharmaceutical companies did not carry out the necessary research and development to 
adapt medicines to the needs of children. The underlying reason being that medicine 
development for paediatric patients is accompanied by numerous challenges for 
pharmaceutical companies, such as the diversity of children in different age groups, the 
consent and recruitment process or the ethical implications. Over the past decades, 
regulatory legislations for drug development in paediatric patients were passed worldwide 
to support the development and administration of appropriate paediatric medicines (see also 
Background Paper 8.2 ‘Regulatory incentives for innovation’). Progress is being made by 
combining requirements for paediatric drug development with market incentives for the 
pharmaceutical industry to (at least partly) cover the additional investment needed for 
testing drugs in children. 
 
4.1 Implementation of the EU paediatric legal framework 
Following the successful example of the United States paediatric initiative, the European 
Union adopted the Paediatric Regulation65 in 2007, with its main provisions coming into 
effect in 2008 and 2009. The regulation aims to improve the health of children in Europe by 
increasing research, development and the authorisation of medicines for paediatric use.66 Its 
policy objectives are as follows:  
 to facilitate the development and accessibility of medicines for use in children 
 to ensure that medicinal products used to treat children are subject to ethical research of 
high quality and are appropriately authorised for use in the paediatric population 
 to improve the information available on the use of medicines in the various paediatric 
populations.66 
 
One key measure of the regulation is the creation of the Paediatric Committee (PDCO), a 
committee of scientific experts within EMA, whose principal task is to assess paediatric 
investigation plans (PIP) submitted by the pharmaceutical industry. A PIP is a development 
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plan which contains full details of the timing and the measures proposed to demonstrate the 
quality, safety and efficacy of the medicines in specified paediatric subsets. An approved PIP 
must always be demonstrated at the time of the marketing authorisation (MA) application 
for new products. This is also true for authorised products where new indications, new 
pharmaceutical forms and new routes are sought. A system of waivers and deferrals has 
been introduced to ensure that the requirements do not delay the authorisation of medicines 
in adults.66 A waiver of the paediatric development can be granted for all (a full waiver) or 
subsets (a partial waiver) of the paediatric population on the basis of the lack of efficacy or 
safety of the medicine, when the disease or condition only occur in adults, or when the 
medicine does not have significant therapeutic benefit over existing therapies. A deferral 
allows postponing the initiation and/or the completion of the PIP measures to ensure that 
research is conducted only when it is safe and ethical and does not delay or block the 
marketing authorisation for adults. 
 
The PIP requirements do not apply to generics. For medicines not yet authorised or still 
covered by intellectual property rights (IPRs), the regulation established rewards and 
incentives, such as a six month extension of the supplementary protection certificate (SPC), 
including adult use. In the case of orphan medicinal products, the incentive is the extension 
of market exclusivity (12 years instead of 10, see also Background Paper 6.19).66 However, the 
additional market exclusivity granted for paediatric medicines may delay generic entry and 
have price implications.  
 
In the case of authorised products no longer covered by IPRs, whose manufacturer 
voluntarily apply for a MA in children, the regulation establishes a new type of marketing 
authorisation, the Paediatric Use Marketing Authorisation (PUMA), which provides data 
protection for a ten-year period. PUMA is granted to off-patent medicines adjusted 
exclusively for use in children to stimulate innovation in treating childhood diseases. It is, 
however, weaker than patent protection and does not guarantee market exclusivity, as 
competitors could carry out their own research and development on the same active 
substance, if they judge the market to be large enough.66 
 
To generate studies on off-patent medicines the regulation provides an opportunity to access 
‘ad hoc’ European funds for research and development through the EU Seventh Research 
Framework Programme (FP7).66 Other PDCO specific functions include establishing an 
inventory of specific needs for paediatric medicinal products and the giving of free scientific 
input into the development of any documents related to achieving the regulation’s 
objectives. 66 
 
In accordance with the Paediatric Regulation, the European Network of Paediatric Research 
at the European Medicines Agency (Enpr-EMA) was set up in 2009 as a network of 38 
national research networks, investigators and centres with expertise in performing clinical 
studies in children.67 The objectives of the European network include coordinating studies 
relating to paediatric medicinal products, building up the necessary scientific and 
administrative competences at a European level, and avoiding unnecessary duplication of 
studies and testing in the paediatric population. There is no specific funding provided 
through the regulation for this European network. The network also works at an 
international level with the World Health Organization through the EMA’s membership in 
the Paediatric Medicines Regulators’ Network (PmNR) and with the U.S. FDA through the 
EMA’s existing interaction on paediatric medicines. The Enpr-EMA still does not cover all 
Update on 2004 Background Paper, BP 7.1 Priority Medicines for Children 
 7.1-25 
paediatric therapeutic areas and needs to foster further research in paediatric cardiology, 
gastroenterology, diabetes, and neonatology.67 
 
There is also public access to information about trials using a paediatric population, 
including those that have been temporarily halted or prematurely terminated, via the EU 
Clinical Trials Register68, launched in 2011, which is also a WHO Registry Network data 
provider.  
 
4.2 Achievements of the EU Paediatric Regulation 
The intended long-term impact of the Paediatric Regulation is the integration of paediatric 
development in the overall area of medicine development. Therefore, the regulation 
demands that each new compound is systematically evaluated during the research and 
development (R&D) process for its potential use in children. Its key measures (PDCO, PIP) 
set norms and standards for the suitable design of paediatric clinical trials in order to ensure 
the development of safe, efficacious, and age-appropriate paediatric medicines.69 As a result, 
some companies have consulted with investigators during the development process, creating 
beneficial links between the industry and the research community. However, the paediatric 
requirements may also put an increased administrative burden on the industry. Moreover, 
many may see the compliance with PIP requirements as a fulfilment of regulatory 
obligations rather than as an establishment of a complete and independent R&D 
programme.70 
 
Based on EudraCT data, the number of clinical trials with children in the European Union 
was stable over time during the period 2007-2011 with an average of 350 trials per year being 
conducted, with the number of trials in all populations declining by about 6% per year. 
(Table 7.1.6) One of the innovations introduced in paediatric research was the inclusion of 
younger children in clinical trials for cholesterol-lowering and anti-hypertensive medicines, 
juvenile idiopathic arthritis, diabetes mellitus, and haemophilia A and B.69 To facilitate 
clinical trials in children or reduce the need for investigation in this vulnerable and limited 
population, it is important to encourage alternative methodological approaches to classical 
clinical trials, such as modelling and simulation techniques. 
The Paediatric Regulation may contribute towards greater transparency in clinical trials by 
preventing unnecessary trials, since the protocol-related information for registered trials is 
made publicly available through EudraCT. 69 
 
Since 2008, approximately 70% of all PIPs evaluated by the PDCO proposed or required 
development of indications for the whole or some subsets of the paediatric population. This 
indicates an increase in the development of medicines for children, as only approximately 
30% of medicines applied for and obtained a paediatric indication before the EU Paediatric 
Regulation came into force.69 Nevertheless, therapeutic areas addressed by PIPs and agreed 
by PDCO primarily cover those diseases that affect adults and children similarly (e.g. 
endocrinology, gynaecology and fertility, metabolism, infectious diseases, oncology, 
cardiovascular diseases). Lamentably, the impact of the regulation on high priority and 
unmet therapeutic paediatric needs, including rare diseases or diseases that occur only in 
children (e.g. paediatric oncology, pain, neonatal morbidity), is not encouraging.69 Only 
about 25% of all agreed PIPs were submitted exclusively for the therapeutic area of 
neonatology despite their having the highest need for medicine development. This indicates 
that paediatric development is significantly dependent on the adult development of 
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medicines, and thereby market oriented, and it does not correspond to unmet paediatric 
needs. 
 
 
Table 7.1.6:Paediatric clinical trials by year of authorisation (or, if not available, by year of 
protocol uploaded into EudraCT)  
 2005 2006 2007 2008 2009 2010 2011 2012 
Paediatric trials (number) 253 315 351 341 401 379 360  
Paediatric trial that are part of an agreed 
PIP* (number) 
1 0 1 4 12 22 70 21** 
Proportion of paediatric trials that are 
part of an agreed PIP among paediatric 
trials* 
0% 0% 0% 1% 3% 6% 19%  
Total number of trials (adults and/or 
children 
3 327 3 951 4 730 4 506 4 411 4 019 3 622  
Proportion of paediatric trials among all 
trials 
7.6% 8.0% 7.4% 7.6% 9.1% 9.4% 9.9%  
* This partial information requires sponsors using a Clinical Trial Application form that was available from 
November 2009 only, for use with version 8 of EudraCT available from 2011. 
** Number of paediatric trials uploaded into EudraCT by 3 April 2012 for authorisation in 2012. 
 
EudraCT Data Warehouse using pre-defined query on 3 April 2012 and counting the first authorised trial only, in 
case of more than one Member State. As National Competent Authorities of Member States upload data into 
EudraCT irrespective of the study population, the year of authorisation is a better indicator of the initiation than 
the year of upload.  
Source: European Medicines Agency. Draft 5-year Report to the European Commission: General 
report on the experience acquired as a result of the application of the Paediatric Regulation. 8 July 
2012 EMA/428172/2012.69 
 
 
 
Between 2008 and 2012, 29 PIPs were completed in compliance with the PDCO decisions, 
which led to 24 new paediatric indications and seven new pharmaceutical forms appropriate 
for children. Centralized authorisations for paediatric use were obtained for 34 new 
medicines (Table 7.1.7), and 38 new paediatric indications, as variations of 33 already 
authorized medicines (Annex 7.1.8). In addition, 14 centrally authorized products had either 
a new pharmaceutical form, a new route of administration, or a new strength authorized for 
paediatric use.69 
 
Rewards were obtained for 12 medicines; supplementary protection certificate (SPC) 
extensions for 11 medicines (Annex 7.1.9), and one PUMA exclusivity was provided for the 
midazolam paediatric oromucosal form.69 As far as incentives are concerned, the value of a 
six-month extension of the SPC can vary widely. It can be economically significant, and even 
excessive, especially in the case of blockbusters, leading to unnecessary additional costs for 
consumers. Here, the introduction of a cap system for ‘super profits’ may be necessary to 
control the cost implications for the healthcare systems.70 Many health workers may even 
prefer to use off-label medicines with the same active ingredient at a lower cost for children. 
The cost implication of the access to improved medicines is put in context of the drug 
development expenditures and the costs related to off label use and lack of available 
medicines. 
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Table 7.1.8: Medicinal products with initial marketing authorisation including a 
paediatric indication  
Year of 
European 
Commission 
Decision 
No. 
in 
year 
Requirement to 
fulfil Paediatric 
Regulation at first 
authorisation 
Indication is 
paediatric-only 
or “mixed” 
(adult and 
paediatric) 
Active substance(s) 
Trade Name 
(®) 
2007 1 No Mixed Retapamulin Altargo 
2007 2 No Mixed Nelarabine Atriance 
2007 3 No Mixed Human papillomavirus 
vaccine [types 16 and 18] 
Cervarix 
2007 4 No Mixed Hydroxocobalamin Cyanokit 
2007 5 No Mixed Idursulfase Elaprase 
2007 6 No Mixed Gadoversetamide Optimark 
2007 7 No Mixed Betaine anhydrous Cystadane 
2007 8 No Paediatric-only Stiripentol Diacomit 
2007 9 No Paediatric-only Mecarsermin Increlex 
2007 10 No Mixed Rufinamide Inovelon 
2007 11 No Mixed Hydroxycarbamide Siklos 
2007  12 No Mixed Human normal 
immunoglobulin (ivig) 
Flebogamma 
DIF 
      
2008 1 No Mixed Fluticason fuorate Avamys 
2008 2 No Mixed Human normal 
immunoglobulin 
Privigen 
2008 3 No Mixed Lacosamide Vimpat 
2008 4 No Mixed Micafungin Mycamine 
2008 5 No Mixed Sapropterin Kuvan 
2008 6 No Mixed Sugammadex Bridion 
      
2009 1 No Paediatric-only Tocofersonal d-alpha 
tocopheryl polyethylene 
glycol succinate 
Vedrop 
2009 2 No Mixed Mifamurtide Mepact 
2009 3 No Mixed Rilonacept Arcalyst 
 
2009 4 No Mixed Tacrolimus Modigraf 
2009 5 Yes Paediatric-only Pneumococcal 
polysaccharide conjugate 
vaccine (absorbed) 
Synfiorix 
2009 6 Yes Mixed Canakinumab Ilaris (PIP not 
yet completed) 
2009 7 Yes Paediatric-only Pneumococcal 
polysaccharide conjugate 
vaccine (13-valent, 
absorbed) 
Prevenar 13 
(PIP not yet 
completed) 
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2010 1 Yes Mixed Meningococcal group a, c, 
w135 and 7 conjugate 
vaccine 
Menveo (PIP 
completed) 
2010 2 Yes Mixed Velaglucerase alfa Vpriv (PIP not 
yet completed) 
      
2011 1 Yes* Paediatric-only Influenza vaccine (live 
attenuated nasal) 
Fluenz 
(Waiver) 
2011 2 Yes Mixed C1 inhibitor, human Cinryze (PIP 
not yet 
completed) 
2011 3 Yes Mixed Dihydroartemisinin/ 
piperaquine phosphate 
Eurartesim (PIP 
not yet 
completed) 
2011 4 Yes (PUMA) Paediatric-only Midazolam Buccolam (PIP 
completed) 
2011 5 Yes** Mixed Everolimus Votubia (PIP 
not yet 
completed) 
2011 6 Yes** Mixed Tobramycin TOBI Podhaler 
(PIP not yet 
completed) 
2011 7 Yes Mixed Nomegestrol/ estradiol  IOA, Zoely 
(PIP 
completed) 
* The PDCO opinion had granted a waiver for the full paediatric population.  
** This was a new marketing authorisation for an orphan designated condition of a medicinal product that was 
already authorised in the EU for non-orphan designated condition(s).  
PUMA = Paediatric use marketing authorisation. 
 
Source: European Medicines Agency. Draft five-year Report to the European Commission: General 
report on the experience acquired as a result of the application of the Paediatric Regulation. 8 July 
2012 EMA/428172/2012.69 
 
 
 
The fact that to date only one PUMA has been granted demonstrates that in practice the 
incentive of 10 years of data exclusivity has not been an attractive option to the industry. 
This concept does not seem financially viable to companies, as the target population for a 
PUMA is too small. Plus, national reimbursement rules may not offer rewards great enough 
to make up for the costs of off-patent medicines. It is also questionable as to whether generic 
companies that hold authorisations for off-patent products have the necessary resources to 
invest in additional research. In addition, it has to be evaluated as to whether PUMA granted 
products have therapeutic benefit over existing treatments. As an illustration, the French 
National Authority for Health rated the midazolam paediatric oromucosal solution 
(Buccolam®) as representing only a minor therapeutic advance for paediatric seizure 
treatment.71 
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In order to identify gaps in paediatric treatments, a survey of all paediatric uses was 
undertaken in the EU in 2010. The objective was to produce an inventory of specific 
therapeutic needs for off-patent paediatric medicines.72 The list includes 16 active 
substances/classes for the following paediatric therapeutic areas: pulmonology/respiratory 
diseases, psychiatry, dermatology, and endocrinology.69 (Annex 7.1.9)  
 
The Paediatric Regulation contains a provision for community funding for research into off-
patent paediatric medicines. The funding is provided through the EU Framework 
Programmes for Research and Technological Development to cover the development of off-
patent medicinal products by submitting PUMAs to PDCO. To ensure that funds are 
directed into research on medicines with the highest need in children in Europe, the PDCO 
adopted the priority list of off-patent products for which studies were required in January 
2012.73 The list includes specific recommendations on areas where data and studies were 
lacking, covering potentially all therapeutic areas and age groups (Cardiology, psychiatry, 
endocrinology, gastroenterology, haematology, immunology, infections, intensive care, 
metabolism, neonatology, nephrology, neurology, oncology, pain, pneumology and 
rheumatology). The list now serves as the basis for the EU Seventh Framework Programme 
(FP7) community funding for research into off-patent medicines. Annex 7.1.10 displays a list 
of 15 funded projects and two investigator-driven clinical trials for off-patent medicines 
(total value of €75 million).69 As illustrated, a number of PIPs have been submitted by 
academia and SMEs and agreed with the PDCO with the view to apply for a PUMA. In 
addition, Annex 7.1.11 presents the remainder of the projects on the use of paediatric 
medicines, which were funded by the Sixth and Seventh Framework Programme (FP6, 
FP7).74 Also, five EU countries introduced specific national paediatric research incentives to 
support paediatric medicines development (Belgium, Finland, France, Malta, Spain, United 
Kingdom).69  
 
Complementary, to address the unmet needs of paediatric medicines, EMA has published a 
range of lists75 covering specific substances within several therapeutic areas (anaesthesiology, 
anti-infectious therapy, cardiovascular diseases, chemotherapy, diabetes, epilepsy, 
gastroenterology, immunology, migraine, nephrology, obstructive lung disease, pain, 
psychiatry, rheumatology). The lists cover substances where off label use in children is 
significant and where data on pharmacokinetics, dosing, efficacy and safety in children is 
highly needed. The inventory is currently under revision, taking into account the EMA 
survey of all paediatric uses of medicines in Europe.72 
 
Five years after the implementation of the Paediatric Regulation, paediatric therapeutic areas 
addressed by the industry seem more aligned with adult drug development than to the 
indicated unmet public health needs of children (paediatric oncology, pain, neonatal 
morbidity). Taking into consideration the lack of financial interest from the industry for the 
PUMA incentive, collecting and analysing existing knowledge on off-label use of medicines 
in children and disseminating the information among health practitioners could prove more 
sustainable (see Section 5 of this background paper). 
 
The introduction of a new paediatric product (resulting from this EU regulation) on the 
market has to be accompanied by adequate regulatory, political and financial decisions at the 
national levels. Some undesirable issues that may have arisen from a deficient handling of a 
paediatric marketing authorisation are illustrated by the case of Cozaar® oral suspension. It 
is a paediatric form of the antihypertensive drug losartan that was given a six-month 
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extension to its market exclusivity in France.71 (Table 7.1.8) It has resulted in higher 
healthcare spending in France than if a generic had been used, while the product is 
unsuitably packaged, difficult to obtain, not reimbursable, and not the standard treatment 
for children with hypertension. 71  
 
 
Table 7.1.8: Undesirable outcomes of the introduction of a new paediatric product on the 
market, an example of Cozaar® oral suspension 
Name of the Medicine Cozaar® oral suspension, paediatric form of the antihypertensive drug 
losartan  
Paediatric Regulation reward  Six-months extension to its market exclusivity in France, including non-
paediatric indications 
Therapeutic use Hypertension, but not standard treatment for hypertension in children 
Packaging and labelling Suspension not ready to use 
Not labelled properly  
Poor quality packaging prone to dosing mistakes (diluting) 
Availability Difficult to obtain from retail pharmacies via wholesalers 
Price implications Company did not ask for inclusion in the French reimbursement list 
Expensive, out-of-pocket expenditure 
High profitability for the company* 
* According to figures from the French national health insurance fund for salaried workers (Cnamts) on 
reimbursement requests in France during 2009, reimbursements for losartan (excluding the losartan + 
hydrochlorothiazide combination) over a 6-month period totalled 27 million euros. 
 
Source: Prescrire. Who Benefits from the European Paediatric Regulation? Response to the European 
Commission’s public consultation on the lessons learnt from the first 5 years of application of the 
Paediatric Regulation. Paris, 2012.71 
 
 
 
4.3 Patients’ participation in the development of paediatric medicines  
In addition to the active participation of two patients’ representatives (families) since 2008 at 
PDCO, in 2011 the EMA initiated an innovative project to facilitate the direct participation of 
children and young people in the PDCO activities. The objective is to involve children and 
young people across a wide age range, disease groups, different Member States and cultural 
groups to provide a new age-appropriate dimension to the scientific aspects of the PIP 
evaluation process. Some of the proposed areas for consultation are as follows:  
 evaluation of individual PIPs; 
 definition of significant therapeutic needs according to therapeutic areas;  
 clinical assessments used as endpoints; 
 invasiveness, frequency and duration of tests; 
 preferences for clinical trial design features: randomisation, placebo, frequency of visits, 
duration of study, number of tests, and medicines of choice; 
 acceptability of route of administrations; and 
 acceptability of formulations / preferred formulation type / palatability / frequency of 
dosing / container closure systems and other packaging issue.  
 
The ‘Concept paper on the involvement of children and young people at the Paediatric 
Committee’ (PDCO) was released in September 2012 for public review, and the expected 
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date for adoption of the outcome is January 2013.76 For more information on stakeholder 
involvement, please see Background Paper Chapter 8.5.  
 
4.4 Conclusions 
Overall, the Paediatric Regulation has put a framework and structure in place to encourage 
an integrated approach to the development of paediatric medicines. As a result, a systematic 
evaluation of each new compound to identify paediatric needs and potential value for 
children, has been embedded into the research and development (R&D) process. Its 
requirements and incentives system have produced initial results, addressing some of the 
complexities associated with paediatric studies and stimulating the paediatric research over 
time. The number of EU clinical trials with paediatric populations was stable during 2007-
2011, and some innovations were introduced in clinical trials, such as the inclusion of 
younger children in certain circumstances. Alternative methodological approaches to 
classical clinical trials should be encouraged to facilitate clinical trials in children or reduce 
the need for investigation in this vulnerable and limited population. That includes the 
modelling and simulation approaches, as well as extrapolation, which depends on basic 
knowledge on specific diseases in children, such as pathophysiology, biomarkers and 
pharmacodynamic end-points.  
 
The Paediatric Regulation led to an authorisation of a number of new paediatric indications 
and new pharmaceutical forms, routes of administration, or strengths for paediatric use. 
However, the current therapeutic areas covered by PIPs seem to be more in alignment with 
adult drug development than with the unmet public health needs in children. Moreover, it 
may be expected that the reward of six-month SPC extension may increase public 
expenditures and have cost implications for the public purse. A recent example has shown 
that a deficient market approval of a new paediatric product at national level may result in 
unsafe due to inadequate packaging and labelling. It is therefore, essential that regulatory 
authorities have robust approval systems in place, including active systems to detect and act 
on effects, resulting from the introduction of new paediatric products on the market.   
 
The fact that only one PUMA (with limited therapeutic benefit) was granted, indicates that 
this reward may not be an adequate incentive to the industry for investments in off-patent 
drug research. This might be linked to reimbursement rules that may not recognize PUMA 
and thus attach little value to old medicines, even if they include new age-appropriate 
formulations. Where little industry interest has been expected, the EU Paediatric Regulation 
includes provisions for public sector research funding for off-patent medicines, and number 
of projects have been already initiated by academia and SMEs. Accordingly, the 
collaboration and active involvement of all stakeholders (governments, regulatory 
authorities, research institutions, pharmaceutical industry, and healthcare facilities) prove to 
be vital to effectively address off-label use of medicines in children. As an alternative to 
clinical trials in children, it may be necessary for healthcare professionals to systematically 
monitor the use of off-label medicines in paediatric clinical practice and share patient records 
to produce robust safety and efficacy data. 
  
It is also expected that the new EU Pharmacovigilance Regulation will support the evidence-
based use of off-label medicines in children, because it includes both marketed and 
unlicensed/off label medicines. Hence, it is important to evaluate the added value of this 
promising regulation with respect to children.  
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To ensure that children’s priority therapeutic needs are met, the Paediatric Committee has 
been producing lists on unmet needs. Complementary, medicines with paediatric indications 
have to represent tangible progress with significant therapeutic benefits in paediatric 
treatment areas. A similar situation was previously observed in the US, when 
pharmaceutical companies did not willingly focus their paediatric R&D efforts on the 
priority needs of children. Consequently, a Best Pharmaceuticals for Children Act (BPCA)77 
was adopted in 2007 to allow the FDA to demand clinical trials on certain medicines (even 
with pre-specified trial design), based on an annual list of needs and priorities in paediatric 
medicines published by the FDA and the National Institute of Health (NIH).  
 
 
5. The usage environment 
This section discusses the common problem of off-label and unlicensed use of medicines in 
children, as well as the appropriateness of medicines used for some specific childhood 
diseases, in different healthcare settings, and at different national income levels. 
Furthermore, this section addresses important issues related to the availability of 
information on medicines used in children and the challenges associated with adherence to 
treatment.  
 
5.1 Off-label and unlicensed use of medicines in children 
Children have been commonly considered “therapeutic orphans” because the majority of 
medicines on the market have not been studied in the paediatric population, nor have they 
been approved by regulatory authorities for use in children. It has been estimated that only a 
third of all authorised medicines approved by the European Medicines Agency over the 
period 1995-2005 were licensed for use in paediatric patients. The main constraints to the 
development of paediatric drugs are ethical concerns, economic barriers, and logistical and 
technical issues.76 As a result, many medicinal products are not available in formulations 
suitable for administration in paediatric patients. This often leaves no alternative for the 
prescriber other than to use adult medicines as off-label (medicines prescribed outside their 
authorised indications with respect to age, dosage, indication or route) or unlicensed 
medicines (modified formulations, extemporaneous preparations, imported or used 
medicines before the authorisation license is granted, or chemicals used for therapeutic 
purposes).78  
 
An EMA survey published in 2010 explored unlicensed and off-label use of medicines in 
children based on data from 20 EU and two non-EU countries covering 50% of the total 
population in Europe.72 Overall, the analysis revealed that 45 to 60% of all medicines used for 
children were used outside their marketing authorisation. Higher rates were reported in the 
premature (up to 90% of medicines) and term neonates, as well as in patients with serious 
conditions and those in intensive care units. The most frequently used off-label and 
unlicensed medicines belong to the following therapeutic classes:  
 antiarrhythmics  
 antihypertensives (renin-angiotensin inhibitors, beta blockers)  
 proton pump inhibitors  
 H2-receptor antagonists  
 antiasthmatics  
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 antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine 
reuptakeinhibitors, tricyclic antidepressants).  
 
Adolescents, mainly in Scandinavia, used high rates of off-label oral contraceptives. Off-label 
antimicrobials (e.g. macrolides, beta lactamines, plus beta-lactamase inhibitors and 
carbapenems) and corticosteroids (dexamethasone) were used extensively in very young 
children. The analysis of dosage forms showed that both oral and parenteral formulations 
were used off-label and unlicensed. Hospitalised children, as well as outpatients, were 
frequently treated with off-label medicines, and (preterm) neonates had the highest unmet 
therapeutic needs.  
 
There were discrepancies across individual countries in the use of unapproved medicines 
due to differences in data collection methods, prescribing habits and a medicine’s regulatory 
status (approved or not, in all or some subsets). For that reason, it should be a requirement 
that approved products be made available in all Member States. Likewise, regulatory action 
is needed to address the general lack of paediatric labelling in the Summary of Product 
Characteristics, and in order to foster the harmonisation of information on product labels 
(e.g. between different manufacturers of the same generic medicines, or different 
pharmaceutical forms and administration routes of the same medicine).  
 
Using medicines that are not licensed means that there is limited available evidence or 
reporting on its safety, quality and efficacy and a potentially increased risk of adverse drug 
reactions (ADRs).79 In 2004, the EMA reported an increased incidence of, seriousness in, and 
underreporting of adverse paediatric drug reactions related to off-label and unlicensed use 
of medicines.80 The ADRs in children have been dominated by anti-infectives, anti-asthmatic, 
and gastrointestinal ADRs, reflecting the most common diseases in children; but central 
nervous system ADRs have been equally common.80  
 
Despite the risks of harm, off-label use of medicines has become an accepted standard of 
medical practice, particularly in paediatric intensive care units, where approved medicines 
are scarce.81,82,83 Denying the use of off-label medicines capable of providing benefits could be 
considered unethical in a given clinical context, especially for life-threatening or severe 
chronic illnesses (e.g. cancer therapy, epinephrine, albuterol, dopamine). Experts and health 
authorities have acknowledged that off-label drug use can be medically appropriate, if the 
benefits outweigh the potential risks.84,85,86  
 
Given the lack of age-appropriate doses and formulations, healthcare professionals may 
change a medicine’s administration route, or manipulate adult dosage forms (e.g. 
segmenting tablets and suppositories, cutting patches, dispersing open capsules, or crushed 
tablets in water, liquid, or food). These practices may affect a medicine’s stability and 
bioavailability, and lead to considerable inaccuracies in dose delivery, causing overdoses 
(potential toxicity) or under-doses (potential inefficacy).87 Dose calculation involves a 
systematic examination of both the available evidence on safety and efficacy and the 
seriousness of the condition being treated. Ideally, the evidence should be from a clinical trial 
and should also include information regarding the minimum effective dose. Unfortunately, 
for many conditions in paediatric patients, this detailed information is not available.86 
 
Although the paediatric regulation imposes special attention to dose selection in paediatric 
clinical trials and evaluation of effective and safe doses in children, paediatric trials remain 
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difficult to accomplish. As children may often not be subject to dose-finding studies, 
empirical scaling from adults to children continues to be the mainstream method for dose 
selection in children. This implies paediatric dosing calculations by adult data extrapolation, 
based on the child’s gestational and postnatal age, clinical condition, weight, and/or body 
surface area.88 All these approaches have disadvantages, determined by differences in 
paediatric physiological development or pharmacodynamic and pharmacokinetic 
characteristics, such as variability due to age, gender, body composition, functionality of 
liver and kidneys and maturation of enzymatic systems throughout the life span from 
neonates to adults. This increases the risk of toxicity due to lack of understanding of the 
ontogeny of metabolic pathways, as for example in neonates and toddlers, or poor efficacy 
due to suboptimal dosing.88 
 
Ideally, children's dose calculations should be based on dose scaling in paediatric trials, or at 
least on established paediatric dosage reference texts and formularies (British National 
Formulary for children–BNFc89 and the WHO Model Formulary for Children90), even though 
these guidelines rely on dosing recommendations from clinical experience and off-label use 
rather than on randomized clinical trials.90 For resource limited settings, the WHO 
recommends simplified dosing regimens for HIV and malaria treatments using a weight-
based formula to predict body-surface area.91  
 
Because any off-label or unlicensed product manipulation includes dose calculations, their 
use has great potential of introducing dosing errors. This is most likely the case in younger 
children, or in neonatal intensive care units, because their weights change rapidly, and the 
appropriate dosing becomes particularly difficult.92 Hence, it is often a real challenge to 
prevent medical errors and to improve patient safety in the paediatric setting.93  
 
In western healthcare systems, electronic prescribing systems are considered to be 
potentially helpful tools for reducing prescribing error rates and even death rates in 
paediatric patients.94 But, as prescribing for children is different in comparison to adults, the 
systems require child-tailored solutions (integrated dose checking and obligatory entry fields 
for indications to check off-label use), as a well as clinical pharmacy interventions to check 
administration routes and dosing.94  
 
More importantly, it can be argued that since off-label use of medicines in children is such a 
common practice, it already relies on sufficient data. Yet, existing electronic patient-level 
registries have not been routinely used to explore the efficiency and effectiveness of off-label 
use in children in a systematic manner. To produce evidence for appropriate evidence-based 
off label use it is important to have precise outcome elements within these electronic systems 
to generate sufficient data on dose, efficacy and safety for off-patent medicines. Hopefully, 
the expanded availability and use of electronic medical records will soon allow researchers 
to link clinical treatments and outcomes with off-label medication prescribing trends in order 
to elucidate the implications of off-label use of medicines in children. (See the Background 
Paper Chapter 8.4 ‘Real life data and learning from practice to advance innovation’ for more 
information.)  
 
5.2 Medicines use in children for specific diseases  
Our focus is on the use of medicines for childhood conditions that are considered to be the 
most relevant to public health and that have the highest medical needs in children. The 
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studies on medicines use in children presented below address the issue of the rational use of 
medicines, which requires that patients receive appropriate medications (safe and effective) 
for their clinical conditions, in doses and formulations suitable to their personal 
requirements, for adequate periods of time, and at the lowest cost to their families and 
communities.95 
 
5.2.1 Use of antibiotics in children 
The majority of drug utilisation studies highlight the high rates of outpatient antibiotic 
prescribing in paediatric populations. Of particular concern is the issue of prescribing 
antibiotics for infections with predominantly viral aetiologies (e.g. most upper respiratory 
infections, diarrhoea) because of the problems with antibiotic resistance.96,97 The 
inappropriate prescribing of antibiotics for children is common in Europe, with marked 
differences being seen between Northern and Southern Europe. This variation is caused not 
only by differences in patient populations, but also by differences in prescribing patterns 
based on differences in prescribers’ and patients’ attitudes toward antibiotics, as well as 
cultural and social factors and health-care systems.98,99 Previous studies have even 
demonstrated considerable variations in antibiotic use in all of the neonatal intensive care 
units (NICUs) in one single country— the Netherlands, a country that is characterised by 
relatively low antibiotic utilisation rates in the EU context. All the while, the recommended 
treatment guidelines for neonatal infections within these NICUs were similar. Such in-
country variations might be explained by the emergence of resistant microorganisms in one 
particular NICU requiring the consequent use of a broad range of different antibiotics, and 
the influence of different antibiotic stewardship on the prescription of antibiotics in a 
NICU.100 Correspondingly, a recent United States study shows high rates of systemic 
antibiotics use that account for one-quarter of all the prescriptions dispensed to the 
paediatric population. Encouragingly, the study demonstrates a 14 per cent decrease in 
paediatric antibiotics utilisation rates from 2002 through 2010. It demonstrated the positive 
results of the numerous national initiatives launched to promote the appropriate use of 
antibiotics, particularly for acute respiratory tract infections, and acute otitis media.101  
 
Urgent interventions for improved antibiotic use include implementation of antibiotic 
stewardship programmes; uniformity in antibiotic policies, including uniformity in dosage 
recommendations; educational programmes; surveillance systems; identification of children 
at risk for antibiotic resistant bacteria colonization; and the linkage of antibiotic usage data to 
antimicrobial resistance data.102 For more information on antimicrobial use, see Background 
Paper Chapter 6.1.  
 
5.2.2 Use of psychotropic medicines in children 
Depression and other psychiatric disorders in paediatric patients can have significant 
consequences if not appropriately treated. Still, there have been ongoing debates on the 
augmented use of psychotropic medicines in children, as well as their safety and efficacy. 
Psychotropic prescribing has risen in both European and American children in the last 
decade, with greater annual prevalence in the USA due to differences in psychiatric 
practices, health service systems and financing and cultural beliefs.103 
 
The selective serotonin reuptake inhibitor (SSRI) antidepressants and the atypical 
antipsychotics have been the most widely used drug subclasses. Yet, psychotropic medicines 
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used in bipolar disorder and attention deficit hyperactivity disorder, for instance, show fair 
short-term risk-benefit ratios and poor long-term benefits, and they still have not been 
properly evaluated for paediatric use. In the past few years, clinicians have recognised the 
side effects of these medications, including metabolic syndrome and diabetes. Concerns 
about the lack of well investigated psychotropic medicines, their side-effects, and the 
increase in children and adolescents receiving these medications, have been raised at all 
levels—parents, clinicians, researchers, the lay press, and government officials.104  
 
One of the biggest worries has been that widely used antidepressant drugs might be 
associated with an increased risk of suicidality in paediatric patients. Although the findings 
of drug-induced suicidality, based on adverse event reporting in paediatric patients during 
short-term treatment with antidepressant drugs, seem to be robust, an overall interpretation 
of this finding and its implications for clinical practice are less clear, as it may result from 
greater reporting of suicidal thoughts and behaviours in these patients. The established 
boxed warning on the risk of suicidality is important in alerting patients and their families to 
the safety risk and in encouraging prescribers to balance this risk with clinical need and 
closely monitor patients.105 
 
The lack of well investigated psychotropic medication for children is serious because it is 
inappropriate to extrapolate from adults due to the still developing paediatric brain and 
central nervous system during adolescence. This field remains relatively unresearched at the 
moment.106 
 
5.2.3 Use of medicines in preterm newborns  
The preterm birth prevalence rate has been increasing in Europe over the last 10 years, 
reaching 7% of all life births in 2010. Although their survival rates have improved, preterm 
infants are at greater risk for health complications in later life, such as cerebral palsy, 
respiratory illnesses, sensorial and motor disabilities, and learning and behavioural 
disorders (see Background Paper Chapter 6.23 for more detailed information on neonatal 
conditions).107 The problem of newborn survival has received greater global attention lately, 
with the UN campaign ‘Every Woman, Every Child’ being launched to prevent preterm 
births and improve the survival and outcome of premature babies.108,109,110  
 
Despite the fact that (preterm) neonates belong to the most vulnerable population, data on 
drug utilisation in neonatal intensive care units are limited. Preterm neonates are often 
multi-morbid, in need of intensive and complex medical care, exposed to a high number of 
drugs (mostly unlicensed or off-label), and at higher risk of adverse drug reactions.111,112 
 
A German study in a neonatal intensive care unit (NICU) specialised in pre-term neonates 
confirmed the complexity of treatment strategies and the polypharmacy patterns as preterms 
received an average of eleven different medicines. Contrary to drug utilisation patterns in 
other newborns, the most frequently prescribed medications for preterms were systemic use 
anti-infectives, and central nervous system and respiratory system drugs.113 All very preterm 
infants received at least one unlicensed or off-label medicine, with no information available 
on their safety and efficacy in preterms in the Summary of Product Characteristics (SmPC). 
In this context, the cardiovascular drugs, including diuretics and anaesthetics/analgesics 
were of major concern.113 Similarly, a recent Estonian hospital study described extensive 
pharmacotherapy in (preterm) neonates, frequent use of off-label and unlicensed medicines 
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and large differences in the neonatal information provided by different sources (BNFc, 
Micromedex and the Estonian SPC).114 Moreover, a United Kingdom study found potentially 
harmful substances and excipients (e.g. ethanol, propylene glycol) in the liquid medicines 
used in a NICU. During treatment, preterm newborns were regularly exposed to 20 different 
excipients that have the potential to cause nerve damage, including ethanol and propylene 
glycol chemicals. The level of the recommended maximum intake of sorbitol was also 
exceeded in the patients when it was calculated according to the baby’s weight.115 The 
European regulatory authorities have recognised this problem and some of the drugs 
frequently given to very preterm infants, such as midazolam, fentanyl, dobutamine, or 
hydrochlorothiazide, were included in their list of priority off-patent drugs.73 
 
The lack of data on safety and efficacy leads to uncertainties in (preterm) neonatal drug 
therapy, so more information is urgently needed for optimal use of medicines prescribed in 
neonates. Randomised controlled trials have conventionally been regarded as the golden 
rule for data collection, but they might be impractical and unethical in neonates because of 
difficulties with randomisation or recruitment. Thus, it seems more appropriate to use the 
vast amount of clinical data that already exists in electronic medical records in order to 
improve the knowledge of safety and efficacy related to the use of medicines in preterm 
neonates.  
 
Another concern is the lack of appropriate formulations for preterm newborns, especially for 
injection antibiotics (e.g. gentamicin), that are often misadministered due to low dosing. 
Therefore, innovations like pre-packaged doses and needle-free technology are needed. 
 
5.3 Use of medicines in children in hospitals 
Recent research has provided new data on the use of medicines in the hospital sector, an area 
generally characterized by a lack of knowledge and transparency. A multicentre study 
(ADVISE) was conducted on paediatric general medical wards in two European (United 
Kingdom, Germany) and three non-European (Malaysia, Australia and Hong Kong) 
hospitals in 2008-2009. On average, the children received three medicines during their 
hospitalization, with antibacterials for systemic use, analgesics, and drugs for obstructive 
airway diseases being the medicines most frequently prescribed to the cohorts.116 
 
A study conducted at a large university hospital in Germany showed that while 
antibacterials for systemic use were prescribed most frequently, their use decreased between 
1999 and 2008, whereas exposure to analgesics and anti-inflammatory drugs increased.117 
Antimicrobials are among the most commonly prescribed drugs in hospitals; therefore, in 
2008 the European Surveillance for Antibiotic Consumption (ESAC) project performed a 
study in the paediatric units of 32 hospitals from 21 European countries. It revealed that a 
third of all paediatric patients were on antimicrobials, with a high proportion of them 
receiving antimicrobial combinations. The ESAC study identified the following targets for 
quality improvements of antimicrobial use in children: reducing the excessive use of 
antimicrobial combinations, high proportion of parenteral antimicrobials, and the long 
surgical prophylaxis times.118 
 
A recent, large United States study showed serious polypharmacy in paediatric inpatients as 
a considerable fraction of them were exposed to five or more medicines, especially those 
patients with rare conditions.119 Drug exposures were more prevalent in those children who 
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were older than one year and in children’s hospitals. The most frequently used drugs and 
therapeutic agents included intravenous fluids, narcotics, antipyretics and analgesics, anti-
infective agents, anaesthetic agents, gastrointestinal drugs, and medicines prescribed as part 
of a newborn’s routine care.119  
 
5.4 Use of medicines in children in developing and transitional countries  
Similarly, the irrational use of medications poses significant challenges in resource poor 
settings. A WHO systematic review from 2007 assessed the progress and impact of 
interventions that have been undertaken to improve the treatment of childhood illness in 
developing countries.120 The report indicated that regardless of the numerous national and 
international efforts, suboptimal treatment patterns of acute childhood diseases continued 
over the past 20 years. There has been improvement in the treatment of acute diarrhoea, 
reflected by an increased use of oral rehydration salts (ORS) and a decreased use of 
antidiarrheals and antibiotics. Optimal pneumonia treatment with appropriate antibiotics 
remained the same over time (80% of patients), while inappropriate use of antibiotics to treat 
viral upper respiratory tract infections (URTI) increased steadily, and malaria treatment with 
appropriate antimalarials deteriorated.120 The use of medicines in the public sector was 
substantially better than in the private sector, but there were longer consultation times, better 
labelling, and better patient knowledge of dosing in the private sector. (Annex 7.1.13) 
Prescribing by the paramedical and nursing staff was similar to that of doctors for the 
common childhood diseases treated in health facilities.120 (Annex 7.1.14)  
 
The review suggests that the most effective interventions are multifaceted; target specific 
behaviours and assess local barriers to changing the behaviours; and take place at the system 
level, as opposed to the individual prescriber level. Effective intervention packages include 
educational materials, interactive lectures, educational outreach visits, audits and feedback, 
reminders, use of opinion leaders, policy changes, and the implementation of clinical 
protocols. (Figure 7.1.4)  
 
In 2009, a systematic review examined interventions for changing physician prescribing 
practices and improving child health with regards to paediatric asthma, antibiotic 
prescription, treatment of malaria, and diarrheal disease.121 Interventions focusing on 
structural changes in the design of current practices (e.g., implementation of a new asthma 
clinical pathway, an asthma peer leader with organization change, or restrictions on 
antibiotic use in a neonatal unit, etc.) were more successful than interventions focused on 
individual provider change (e.g., an educational conference for providers, or distribution of 
clinical practice guidelines to physicians).121 As expected, multi-faceted interventions tended 
to be more successful than single interventions.121  
 
Many industrialised countries have adopted activities to promote the more appropriate use 
of medicines, but it seems that their impacts have rarely been thoroughly evaluated. The 
WHO systematic review demonstrates that systematically collected and evaluated evidence 
provides a valuable opportunity for measuring medicine use within health systems and for 
testing the effectiveness of interventions to improve the use of medicines. Such studies are 
therefore also warranted in Europe. 
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Figure 7.1.4: Median reported percentage change across all prescribing outcomes for well-
designed paediatric prescribing improvement interventions, by type of intervention.  
  
Source: World Health Organization. Medicines use in primary care in developing and transitional 
countries: Fact book summarizing results from studies reported between 1990 and 2006. 
WHO/EMP/MAR/2009.3.120 
 
 
 
5.5 Adherence to treatment in children  
Poor compliance to medical regimens may have serious consequences for paediatric patients 
in terms of their health outcomes. Non-adherence may compromise the efficacy of drug 
regimens, thus diminishing the desired treatment goal, or may lead to changes in treatment 
regimens or dosages and an increase in toxicity, unnecessary investigations, and treatment 
costs. Estimates of non-compliance in children and adolescents (40-75%) are greater than in 
adults, particularly in adolescents.122,123,124 
 
Many factors affect medication adherence and in most cases there are multiple causes. 
Factors affecting adherence may be related to illness and treatment regimens; characteristics 
of an individual child, including its age, race, socioeconomic status, developmental level, 
and psychopathology; and characteristics of the family system in which the child 
lives.125,126,127 Importantly, children need appropriate parental and professional support in 
taking control of their medication and treatment.125,126,127 (Table 7.1.9) A survey in the 
Netherlands in a multicultural population of children with asthma indicated that adherence 
to inhaled corticosteroids in children was a particular problem amongst ethnic minority 
patients, but further studies were recommended to clarify the causal mechanism.128 
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Table 7.1.9: Important factors and considerations for adherence to treatment in children   
Reasons and barriers for non-adherence with medicines in children 
The demands of daily schedules of activities, stress, and family dynamics  
Parents' lack of understanding about the diagnosis, concerns about drug therapy effectiveness, and fears about 
medication side effects  
Age, socioeconomic status, race, and family factors  
Language barriers and low health literacy 
 
Considerations for improved adherence with medicines in children 
The triangle of communication between health professionals, parents , and children 
The medication regimen should be tailored to the child and family's lifestyle and daily routine, taking into 
account the frequency and timing of administration 
Consideration should be given to the palatability and formulations of medications prescribed for young children 
Reinforcement of instructions by pharmacists or nurses, medication technique training (e.g., inhaler, injection, or 
dropper use) 
 
Sources: Gardiner P, Dvorkin L, Promoting Medication Adherence in Children American Family 
Physician www.aafp.org/afp. Accessed April 29, 2013.125  
Matsui D. Current Issues in Pediatric Medication Adherence. Pediatr Drugs 2007; 9 (5): 283-288.126 
 
 
 
There has been limited research on the most effective methods for improving adherence to 
recommended treatment in children.129 Methods that have proven to be successful in 
improving adherence in children were, as is also the case in adults, usually multifactorial 
and include: educational programmes, including information on the disease; explaining the 
purpose and potential benefits of the recommended medication; behavioural programmes 
that reward good compliance; and good supportive relationships and therapeutic alliances 
between patient and health professionals that include effective communication. Simplified 
regimens (with minimum effect on lifestyle) and palatable medications with age-appropriate 
formulations and delivery mechanisms may enhance the ability of paediatric patients to 
adhere to their medicines.125125,126,127  (Table 7.1.9) 
 
In addition, pharmaceutical companies have been developing innovative, child-friendly 
preparations appropriate for administration to infants and young children in terms of taste, 
formulation, and route of administration. But, the effects of newer formulations, such as 
effervescent and chewable dosage forms, granules and sprinkles, and the novel delivery 
system (Sip-Technology, that provides ready, easy-to-use, pre-measured dose of medication 
in a straw) are largely untested with regards to medication adherence, as previously stated in 
section 3 of this background paper. 
 
Although there is no consensus as to what is the best approach to promote adherence with 
therapy, attention should be given to determining what barriers exist and trying to overcome 
them by involving children and their parents in the treatment planning process. It has even 
been suggested that perhaps perfect adherence is an ideal that will never be achieved, and 
that maybe the focus should be on determining how much adherence is enough to achieve 
the therapeutic goal. Further research in this direction is encouraged.126  
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5.6 Availability of information on (off-label) paediatric medicines and its 
dissemination to health workers and patients 
One implication of the frequent, off-label use of paediatric medicines is the lack of adequate 
information about their possible indications, dosing regimens, dose adjustments, and 
administration. This information is neither included in the Summary of Product 
Characteristics (SmPC) for health-care professionals, nor in the patient information leaflets 
from the manufacturers or the media information resources for patients and their 
families/caregivers.  
  
Historically, the lack of adequate information on paediatric medicines has been attributed to 
deficient scientific evidence to prescribe medicines in children, but nowadays there are also 
delays in updating the SmPCs with recently generated data. In order to provide better 
information on the use of medicines in children, the Paediatric Regulation has included an 
instrument for collecting existing paediatric studies. The Regulation has obliged companies 
holding data on the safety or efficacy of authorized medicines in children, as well as newly 
generated paediatric data, to submit those studies to the competent authorities, so that data 
can be assessed and authorized product information amended.66 Since 2008 more than 18 000 
study reports on 2 200 medicinal products have been submitted to the competent authorities, 
revealing the large amount of existing paediatric information available at company level. 
These study reports are being assessed by the authorities, resulting in the publishing of 
assessment reports on 140 active substances, and recommending changes to the SmPC for 
authorized products. However, marketing authorisation holders have not progressed much 
in updating the SmPC, so little of those new data have been systematically included in the 
SmPC.69 
 
There have been recent improvements regarding information dissemination on medicine use 
in children for both healthcare workers and the public. The website ‘Paediatric Medicines in 
the Netherlands’130 is a multidisciplinary knowledge network initiated by the Dutch 
Knowledge Centre for Pharmacotherapy in Children (NKFK) and supported by the Ministry 
of Health, Welfare and Sport. The NKFK focuses primarily on improving the provision of 
information on the use of medicines in children to health professionals. Furthermore, the 
British National Formulary for Children89 and the WHO Model Formulary for Children90 
provide dosage information for medicines used off-label in children. Patient information for 
unlicensed and off-label medicines is also available on the website ‘Medicines for children’, 
which consists of medicine information leaflets and provides opportunities for interactions 
between professionals and the public.  
 
These encouraging developments should be supported by complementary research further 
exploring how healthcare professionals obtain their information to adequately treat children 
in daily practice and how this information becomes updated on a regular basis. In addition, 
more should be invested in evaluating the impact of existing information on medicine use in 
children to improve clinical practice and the adherence to treatments in children. 
 
  
Update on 2004 Background Paper, BP 7.1 Priority Medicines for Children 
 7.1-42 
6. Identified gaps and recommendations for research and policy  
 
Since 2004, numerous activities have been undertaken to support the development and 
administration of appropriate paediatric medicines and to improve the information available 
on their use. As a result, a legal EU framework has been put into place to encourage 
paediatric research, and various innovative, age-appropriate formulations, and drug devices 
for paediatric use have followed. Despite rapid technological advances and emerging 
networks for collaborations and expertise, we identified the following knowledge gaps and 
areas that need strengthening and/or future research in the area of medicine use in children.  
 
Collection of data on disease burden and medicine use in children across Europe 
In order to understand the burden of childhood diseases in the EU and set priorities, the 
collection of data on disease prevalence rates, and the use of medicines in children at a 
country level would allow inter-country comparisons and EU analysis of trends and 
variations over time. The main challenges for a complete and comprehensive evaluation are 
the lack of systematic and continuous monitoring in all EU countries and the disparity 
between studies. Therefore, the methodological quality of data collection should be 
improved and more multinational collaborative studies should be performed with EU 
support.  
 
Further research into development of age-appropriate medicines 
In recent years, much progress has been made in the development of age-appropriate novel, 
oral formulations with dose flexibility (mini-tablets, chewable, and orodispersible tablets for 
younger children, and dosage forms dispersible into liquids or mixed with food) and 
medical devices for easier administration of paediatric medicines. The ongoing research on 
the ability of children to swallow solid oral forms needs to be accompanied by studies on 
children’s preferences and adherence to different dosage forms. In addition, new routes of 
administration, such as oral-transmusosal (buccal strips), intra-nasal and transdermal routes 
(for neonates mainly), are ripe for future development and research. In neonates, particular 
caution should is needed for these forms in terms of optimal use and dosing. 
 
Given the safety and toxicity concerns of some excipients in paediatric formulations, more 
research is needed into alternative safe alternatives for children. It is also important to 
incorporate the available knowledge on excipients into a single, public repository to avoid a 
duplication of efforts and to encourage further discovery and innovation.  
 
Study effects of development of age-appropriate medications and paediatric regulations 
Irrespective of all technological developments, there is limited evidence on the impact of 
pharmaceutical formulations, routes, and dosage forms on patient-related outcomes (e.g. 
clinical efficacy, side effects and tolerability, and patient preference, acceptance, and 
adherence). This research should be central to the support of the pharmaceutical 
development of paediatric medicines with clear clinical advantages.  
 
In addition, although many novel formulations and paediatric drug delivery devices have 
been developed, very few appear to be available on the market. This is most likely due to the 
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high costs of patent protection and the (un)willingness of health insurance bodies to 
reimburse for these new items. Therefore, current formulation research should also be 
accompanied by studies on price implications and access to innovative products that have 
tangible therapeutic benefit. Moreover, some paediatric medicines awarded six-month SPC 
extensions have cost implications and may increase public health expenditures. It is therefore 
essential that regulatory authorities have active systems in place to detect and act upon, 
resulting from the introduction of new paediatric products on the market.  
 
Increase efficiency of the Paediatric Regulation with a focus on real paediatric needs 
The Paediatric Regulation aims to achieve an integrated approach to the development of 
paediatric medicines in the overall medicine development area. However, current PIPS and 
their therapeutic areas covered by the industry seem to be more in alignment with adult 
drug development than with unmet public health needs in children (e.g. paediatric oncology, 
pain, neonatal morbidity). As a response, the Paediatric Committee has been producing lists 
on unmet therapeutic needs in children to identify priority research areas. This activity 
should be complemented by proactive demands for clinical trials on priority medicines with 
significant therapeutic benefits in children. 
 
In addition, alternative methodological approaches to classical clinical trials should be 
encouraged to facilitate and optimize clinical trials in children, and potentially also reduce 
the need for (or size of) clinical trials in this vulnerable and limited population. Research in 
this field should be stimulated.  
 
The new EU Pharmacovigilance Regulation may have potential added value in providing 
safety and efficacy data on off-label-medicine use in children, which should be evaluated. 
 
Improve (information on) rational use of paediatric medicines 
Various studies on medicine use trends and patterns in children indicate that more efforts 
are needed to guarantee the rational use of medicines, especially antibiotics, psychotropic 
medicines, medicines for neonates, and medicines used in hospitals. Effective interventions 
that are multifaceted and that take place at the system level must be considered in order 
improve the use of medicines. In addition, data should be systematically collected and 
evaluated to measure and to test the effectiveness of interventions in improving 
medicine use.  
 
The off-label use of medicines has become an accepted standard of paediatric medical 
practice, particularly in areas where approved medicines are scarce. But, due to the lack of 
clinical trials using children, the available evidence on safety, quality, and efficacy and the 
knowledge of the potential risks of adverse drug reactions with off-label medicines used in 
children is limited. On the other hand, existing, electronic, anonymised, patient-level 
registries have not been used to explore the efficiency and effectiveness of off-label use in 
children. It is therefore essential to systematically collect and use the real life data on off-
label or unlicensed medicine use in children to produce the evidence. Hopefully, the 
expanded availability and use of electronic medical records will soon allow researchers to 
link clinical treatments and outcomes with off-label medication prescribing trends and 
elucidate the implications of their use in children.  
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There has also been limited evidence on the most effective methods for improving adherence 
to recommended treatments in children. More research is needed to identify adherence-
promoting interventions in children, and to evaluate their impact. 
 
Recent improvements in information dissemination on medicine use in children for both 
healthcare workers and the public include the creation of websites (‘Paediatric Medicines in 
the Netherlands’ and ‘Medicines for Children’ in the United Kingdom), the BNFc and the 
WHO Model Formulary for Children. Complementary research should follow up on this to 
evaluate how healthcare professionals obtain information to treat children in daily practice 
and to evaluate what impact new information resources have on the use of medicines and 
adherence to treatment in children. 
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Annex 7.1.1: Infant mortality rates in Europe in 2010 
 
 
 
 
Source: European Commission and the Organisation for Economic Co-operation. Health at a Glance: 
Europe 2012.  OECD Publishing, 2012.  
http://ec.europa.eu/health/reports/docs/health_glance_2012_en.pdf. Accessed May 2, 2013.3 
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Annex 7.1.2: Regional causes of childhood deaths in 2010 
 
 
 
Source: Liu L, Johnson HL, Cousens S, et al, for the Child Health Epidemiology Reference Group of 
WHO and UNICEF.  Global, regional, and national causes of child mortality: an updated systematic 
analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151–61.4  
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Annex 7.1.3: Developmental Changes in Physiology in Children 
 
 
 
Source: Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental Pharmacology – drug disposition, action, and therapy in infants and children. N Engl 
J Med 2003;349:1157-1167.35 
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Annex 7.1.4: EMA Matrix – routes of administration/dosage form versus age 
 
 
(1–not applicable, 2–applicable with problems, 3– probably applicable, but not preferred, 4– good applicability, 
5 – best and preferred applicability)  
 
 
Source: European Medicines Agency. Reflection Paper on Formulations of Choice for the Paediatric 
Population (EMEA/CHMP/PEG/194810/ 2005).38 
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Annex 7.1.5: Novel drug formulations for children   
 
Dosage form Brand product (manufacturer) 
Multiparticulates 
Granules / Sprinkles / 
Pellets 
Pankreatin Kreon® (Kali-Chemi Pharma), artesunate and mefloquine granules - 
Artequin® Pediatric (Mepha), methylphenidate granules – Medikinet® (Medice) 
 
Mini-tablets Pankreatin - Pankreatan® (Novartis) Cholspasminase ® (Merck) 
Enzym-Lefax® (Bayer) 
Cotazym® (UCB),  
Methylphenidate controlled release – Ritalin® pellets (Sandoz) 
Concerta® trilayer (J&JPRD) 
Flexible dispersible formulations 
Dispersible tablets ACT-Coartem® Dispersible (Novartis,MMV) 
Sinupret® Liquitabs® (Bionorica) 
Oral lyophilisates Cetirizine - Zyrtec® (Duncan) 
Orally disintegrating 
tablets- lozenges 
Sodium fluoride - Fluoretten® (Sanofi-Aventis) 
Oral strips / Buccal 
wafers 
Dextromethorphan, acetaminophen - Triaminic® (Novartis) 
Ondansetro - Setofilm® (Applied Pharma Research & Labtec & Monosol Rx) 
Chewable tablets Magnesium hydroxide gummy bears-Pedia Lax® (Fleet) 
Montelukast sodium – Singulair® (MSD) 
Chewing gums Dimenhydrinate - Superpep® (Hermes) 
Medicated lollipop Fentanyl citrate - Actiq® (Cephalon) 
Orally disintegrating 
mini-tablets 
Hydrochlorothiazide-Ludiflash®, Sodium stearylfumarate - Pruv® (JRS) 
 
 
 
Sources: Stoltenberg I, Winzerburg G, Breitkreutz J. Solid oral forms for children – formulations, 
excipients and acceptance issues. Journal of Applied Therapeutic Research, 2010; 7(4): 141-146.43 
 
Breitkreutz J. Nach der EU-Reform. Arzneiformen für Kinder. Pharm. Unserer Zeit 2009;38: 30-37.45 
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Annex 7.1.6: Novel drug devices for children 
 
Dosage form Brand product (manufacturer) 
Novel dosing instruments for oral liquids 
Teat/Pacifier with reservoir Nystatin suspension, Mykundex® (Bioglan) 
Single-use spoon filled with 
medicine 
Diphenhydramin solution,BenadrilTM® (Pfizer) 
Dropper tube Codeine drops (Stella / Abbott) 
Dose sipping technology – straw 
with taste 
Clarithromycin micropellets Clarosip® (Grünenthal GmbH) 
Solid dosage pen Carvedilol, salutas and metoprolol tartrate, microsinused as model drugs 
Coated particles for oral administration 
Coated particles in suspension Clarytromycin (Abbott) 
Coated particles in tablets for 
preparing suspension 
Roxithromycin (Infectopharm) 
Coated particles on dosage spoon Pre-dosed azithromycin spoon (Sandoz) 
Needle-free injection devices 
Jet injectors Subcutaneous administration of insulin, vaccines, growth hormone Saizen® 
(Bioject and Serono) 
Microstructured transdermal 
systems for intradermal vaccines 
 
Novel devices for inhalation therapy 
Nebuliser with spacer/valved 
holding chamber and face mask 
 
Nebulisers with a vibrating mesh 
technology for aerosol generation 
 
Nebuliser with an electronic unit For antibiotics e.g. tobramycine, Pari Boy® - electric nebuliser with 
compressor and face mask, AeroChamber® Plus (VHC) 
Ventolair Autohaler for beclomethasone dipropionate 
Dry powder inhalers  
 
Flutide Diskus® 50 with fluticasone propionate, (GSK) 
Inhalation-driven multidose dry powder inhaler with micronized 
budesonide (AstraZeneka), Pulmicort Resules® with micronised 
budesonide suspension for inhalation 
 
 
Sources: Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Exp Opin Drug Deliv 2007; 4:37–
45.39 
 
Walsh J,Bickmann D, Breitkreutz J, Chariot-Goulet M, on behalf of the European Paediatric 
Formulation Initiative (EuPFI). Delivery devices for the administration of paediatric formulations: 
Overview of current practice, challenges and recent developments.  International Journal of 
Pharmaceutics 2011;415:221– 231. 51 
 
Annex 7.1.7: Paediatric products prequalified up to 2012  
 
 Abacavir (as sulfate) 60 mg 
 Lamivudine/Nevirapine/Stavudine 60 mg/100 mg/12 mg 
 Lamivudine/Nevirapine/Stavudine 30 mg/50 mg/6 mg 
 Lamivudine/Nevirapine/Zidovudine 30 mg/50 mg/60 mg 
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 Isoniazid/Pyrazinamide/Rifampicin 30 mg/150 mg/60 mg 
 Artemether/Lumefantrine 20 mg/120 mg 
 Lamivudine – 30 mg - Dispersible tablets  
 Lamivudine – 30 mg – Tablets 
 Zidovudine – 100 mg - Tablets  
 Isoniazid/Rifampicin – 60 mg/60 mg - Dispersible tablets  
 Abacavir (as sulfate)/Lamivudine – 60 mg/30 mg – Tablets 
 Nevirapine   50 mg/5 ml  - Oral suspension 
 Lopinavir/Ritonavir   100 mg/25 mg   - Tablets  
 Abacavir (as sulfate)/Lamivudine/Zidovudine   60 mg/30 mg/60 mg - Tablets 
 Lamivudine/Zidovudine   30 mg/60 mg - Tablets  
 
 
Source: World Health Organization. Prequalification Programme, A United Nations Programme 
managed by WHO. 2011; Available at: http://apps.who.int/prequal/. Accessed May 2, 2013.64 
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Annex 7.1.8: List of centrally authorised medicinal products for which the 
therapeutic indication was extended or amended to the paediatric 
population. 
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Source: European Medicines Agency with its Paediatric Committee. 5-year Report to the European 
Commission. General report on the experience acquired as a result of the application of the Paediatric 
Regulation. EMA/428172/2012 2012; Available at: http://ec.europa.eu/health/files/paediatrics/2012-
09_pediatric_report-annex1-2_en.pdf. Accessed May 2, 2013.69 
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Annex 7.1.9: List of medicinal products and companies that have benefited 
from the 6-month extension of the supplementary protection certificate. 
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Source: European Medicines Agency with its Paediatric Committee. 5-year Report to the European 
Commission. General report on the experience acquired as a result of the application of the Paediatric 
Regulation. EMA/428172/2012 2012; Available at: http://ec.europa.eu/health/files/paediatrics/2012-
09_pediatric_report-annex1-2_en.pdf. Accessed May 2, 2013.69 
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Annex 7.1.10: Funded off-patent medicine projects (start up to 1 January 
2010) and agreed PIPs, if available. 
 
 
Update on 2004 Background Paper, BP 7.1 Priority Medicines for Children 
 7.1-77 
 
 
Source: European Medicines Agency with its Paediatric Committee. 5-year Report to the European 
Commission. General report on the experience acquired as a result of the application of the Paediatric 
Regulation. EMA/428172/2012 2012; Available at: http://ec.europa.eu/health/files/paediatrics/2012-
09_pediatric_report-annex1-2_en.pdf. Accessed May 2, 2013.69 
 
Information available on the website page: http://bit.ly/wUpuOb and http://bit.ly/xTshyn. Accessed 
May 3, 2013. 
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Annex 7.1.11: Therapeutic needs in the paediatric population according to 
the survey of all paediatric uses (EMA/794083/2009) and projects addressing 
the needs  
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Source: European Medicines Agency with its Paediatric Committee. 5-year Report to the European 
Commission. General report on the experience acquired as a result of the application of the Paediatric 
Regulation. EMA/428172/2012 2012; Available at: http://ec.europa.eu/health/files/paediatrics/2012-
09_pediatric_report-annex1-2_en.pdf. Accessed May 2, 2013.69 
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Annex 7.1.12: Projects on use of paediatric medicines funded by the Sixth 
and Seventh Framework Programme (FP6, FP7), excluding off-patent funded 
projects, presented in Annex 7.1.8 
 
No Project name Period  Objective  
FP6 
1 PRIOMEDCHILD 2007-
2010 
Coordination of research on priority medicines for children 
2 EUROSTEC 2007-
2011 
Soft tissue engineering for congenital birth defects in children: new 
treatment modalities for spina bifida, urogenital and abdominal wall 
defects  
3 KIDSCANCERKINOME 2006-
2010 
Selecting and validating drug targets from the human kinome for 
high risk paediatric cancers  
4 CHILDHOPE 2006-
2010 
Chimaeric T-cells for the treatment of paediatric cancers  
5 TEDDY 2005-
2010 
Optimise paediatric use of current drugs and promote the 
development of new drugs, by incorporating pharmacogenetic 
applications and implementing guidance/tools to perform paediatric 
research. 
FP7 
1 DIRECT 2008-
2010 
Disseminate research funded by EC for improving treatment options 
for children suffering from cancer 
2 GRIP 2011-
2015 
Coordinate knowledge management efforts and integrate existing 
research capacity for development and safe use of medicine in 
children, work closely with families to provide children with safe 
and effective medicines. 
3 CUREHLH 2008-
2011 
Establish earlier diagnosis, learn about pathophysiology, and 
develop less toxic treatments for the rare disease haemophagocytic 
lymphohistiocytosis  
4 RESPECT 2008-
2011 
Clarify expectations and needs of children and families to 
participation in clinical trials, empower and motivate children in 
future clinical trials research. 
5 PHARMACHILD 2011-
2014 
Study pharmacovigilance for adverse effects in childhood arthritis 
from treatment with immune modulatory drugs 
6 PANCARESURFUP 2011-
2016 
Collect data on long-term complications of cancer treatments, create 
European cohort for early identification and management of 
complications to improve health and quality of life and maximise use 
of health services  
7 STOP 2011-
2014 
Assess and monitoring of Medication-Related Suicidality in children 
and adolescents in three paediatric observational trials (risperidone 
in conduct disorder; fluoxetine in depression, and montelukast in 
bronchial asthma)  
8 ADDUCE 2010-
2015 
Investigate long-term adverse effects of methylphenidate on growth, 
neurological system, psychiatric states and cardiovascular system in 
children and adults  
9 ENCCA 2011-
2014 
Establish European network for cancer research in children and 
adolescents, define research strategy facilitate clinical trials to 
introduce the new generation of biologically targeted drugs  
 
Source: European Commission. CORDIS (Community Research and Development Information 
Centre) European R&D Projects funded under FP6 and FP. 
http://cordis.europa.eu/projects/home_en.html Accessed May 2, 2013.74 
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Annex 7.1.13: WHO/INRUD prescribing indicators by health facility 
ownership  
 
WHO- World Health Organization, INRUD - International Network for the Rational Use of Drugs EML – 
Essential Medicines List 
 
Source: World Health Organization. Medicines use in primary care in developing and transitional 
countries: Fact book summarizing results from studies reported between 1990 and 2006. 
WHO/EMP/MAR/2009.3. WHO Geneva, 2009.  Available at: 
http://www.who.int/medicines/publications/primary_care_8April09.pdf. Accessed May 2, 2013.120 
 
 
Update on 2004 Background Paper, BP 7.1 Priority Medicines for Children 
 7.1-82 
Annex 7.1.14: WHO/INRUD prescribing indicators by prescriber type 
 
 
WHO - World Health Organization, INRUD - International Network for the Rational Use of Drugs EML – 
Essential Medicines List 
 
Source: World Health Organization. Medicines use in primary care in developing and transitional 
countries: Fact book summarizing results from studies reported between 1990 and 2006. 
WHO/EMP/MAR/2009.3. WHO Geneva, 2009.  Available at: 
http://www.who.int/medicines/publications/primary_care_8April09.pdf. Accessed May 2, 2013.120  
 
